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ABSTRACT
Fanconi anemia (FA) is a rare autosomal and X-linked recessive disorder,
characterized by congenital abnormalities, pediatric bone marrow failure and cancer
susceptibility. FA is caused by biallelic mutations in any one of 16 genes. The FA
proteins function cooperatively in the FA-BRCA pathway to repair DNA interstrand
crosslinks (ICLs). The monoubiquitination of FANCD2 and FANCI is a central step in
the activation of the FA-BRCA pathway and is required for targeting these proteins to
chromatin. Despite their critical role in ICL repair, very little is known about the
structure, function, and regulation of the FANCD2 and FANCI proteins, or how they
are targeted to the nucleus and chromatin. The goal of this dissertation is to study the
mechanisms and regulation of FANCD2. Through this research, we have uncovered a
nuclear localization signal (NLS) in FANCD2. Mutation of this NLS region impairs
FANCD2 and FANCI monoubiquitination and inhibits the recruitment of FANCD2
and FANCI to chromatin. In addition, we have identified a putative CDK
phosphorylation site cluster in FANCD2. Taken together, we believe these findings
have enhanced our understanding of this important DNA repair protein and will allow
for further investigation of this rare cancer susceptibility syndrome.
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PREFACE
The following dissertation has been prepared in manuscript format. Chapter 1,
“The Fanconi Anemia ID2 Complex: Dueling Saxes at the Crossroads”, was published
in Cell Cycle and is a review encompassing our current understanding of the
regulation and function of the FANCD2 and FANCI proteins. Chapter 2, “Coordinate
Nuclear Targeting of the FANCD2 and FANCI Proteins via a FANCD2 Nuclear
Localization Signal” was published in PLoS One. Chapter 3, “Characterization of a
Putative CDK Phosphorylation Site Cluster in the FANCD2 Protein” was prepared for
submission to PLoS Genetics.
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Fanconi anemia (FA) is a rare recessive genetic disease characterized by
congenital abnormalities, bone marrow failure and heightened cancer
susceptibility in early adulthood. FA is caused by biallelic germ-line mutation of
any one of 16 genes. While several functions for the FA proteins have been
ascribed, the prevailing hypothesis is that the FA proteins function cooperatively
in the FA-BRCA pathway to repair damaged DNA. A pivotal step in the
activation of the FA-BRCA pathway is the monoubiquitination of the FANCD2
and FANCI proteins. Despite their importance for DNA repair, the domain
structure, regulation, and function of FANCD2 and FANCI remain poorly
understood. In this review, we provide an overview of our current understanding
of FANCD2 and FANCI, with an emphasis on their posttranslational
modification and common and unique functions.

The Discovery of FANCD2 and FANCI
FANCD2
The FANCD2 gene was identified in 2001 by the Grompe, D‟Andrea, and Moses
Laboratories using a positional gene cloning approach, following many years of
collaborative efforts.1-4 The PD20 FA patient line was originally assigned to the FA-D
complementation group because of its inability to complement the mitomycin C
(MMC) hypersensitivity of the FA-D reference line HSC62.4-6 Using a microcellmediated chromosome transfer approach, the FANCD gene was initially mapped to
3p22-26.4 Hejna and colleagues subsequently narrowed the critical region to ~200 kb,
a region which harbored three candidate genes: TIGR-A004X28, SGC34603, and
3

AA609512.2 Timmers and colleagues then used rapid amplification of cDNA ends
(RACE) to obtain the respective full-length cDNAs and sequenced these three genes
in the PD20 cells.1 No sequence changes were uncovered in A004X28 and AA609512.
However, five sequence changes were found in SGC34603; three of which represented
common polymorphisms and two represented bona fide mutations. One sequence
alteration was a maternally inherited A to G transition at nucleotide 376, which
resulted in a S to G missense change. This transition was also associated with
missplicing and insertion of 13 nt from intron 5 into the mRNA, causing a frameshift
and production of a severely truncated protein. A second paternally inherited sequence
change in SGC34603 resulted in an R to H missense and hypomorphic change at
position 1236 (R1236H),1 strongly suggesting that SGC34603 was indeed the FANCD
gene. Confirming this, transduction of PD20 cells with full-length wild-type FANCD
rescued the MMC hypersensitivity of these cells.1 No sequence changes in SGC34603
however were uncovered in HSC62. These findings led to the delineation of two FA-D
complementation groups, FA-D1 and FA-D2, with biallelic mutations in
SGC34603/FANCD2 causative for the FA-D2 complementation group.1 Early
biochemical studies of the FANCD2 protein uncovered two isoforms: an unmodified
form and a higher molecular mass isoform posttranslationally modified through the
covalent

attachment

of

a

single

ubiquitin

polypeptide,

referred

to

as

monoubiquitination.3

FANCI
The existence of the FA-I complementation group was first established by Levitus and

4

colleagues, on the basis of somatic cell hybrid complementation analyses,7 and the
FANCI gene was subsequently identified by three groups in 2007.8-10 Using a two-step
genome-wide linkage approach with four genetically informative families, Dorsman
and colleagues identified four candidate regions encompassing 39.4 Mb and
comprising 351 genes. The sequencing of several candidate DNA repair genes failed
to reveal sequence alterations. However, two strong alternative candidate genes KIAA1794/NP_060663 and C15orf42/NP_689472 - were interrogated due to their
resemblance to known FA genes in their extent of evolutionary conservation and the
presence of nuclear localization signals, as many FA proteins, including FANCD2,
were known to be nuclear.3, 11-14 Sequencing of the KIAA1794 gene in all eight FA-I
patients uncovered pathogenic mutations.8
Employing a phosphoproteomics screen to identify substrates of the DNA
damage response kinases ATM (ataxia-telangiectasia mutated) and ATR (ATM and
Rad3-related), the Elledge group identified KIAA1794 as an ionizing radiationinducible phosphoprotein.15 An amino acid sequence alignment of KIAA1794/FANCI
and FANCD2 uncovered a modest overall 13% identity and 20% primary sequence
similarity. However, a higher degree of sequence conservation was revealed in the
region encompassing KIAA1794/FANCI K523 and that flanking FANCD2 K561, the
site of FANCD2 monoubiquitination.3, 10 Subsequent experiments established that, like
FANCD2, FANCI is monoubiquitinated following treatment of cells with DNA
damaging agents and during S phase of the cell cycle.10 While full-length
KIAA1794/FANCI protein was detected by immunoblotting in BD0952, an EpsteinBarr virus-transformed lymphocyte line from an FA patient of unassigned

5

complementation group, monoubiquitinated FANCI was not detected in these cells.
DNA

sequencing

revealed

homozygosity

for

two

base

substitutions

in

KIAA1794/FANCI in BD0952 cells. These included a C to T transition leading to a
P55L amino acid change, and a G to A transversion leading to a R1285Q change, the
latter representing the pathogenic mutation.10
In an alternative strategy, Sims and colleagues performed a BLAST search
using the conserved amino acid sequence flanking the site of FANCD2
monoubiquitination

K561,

LVIRK,

to

identify

proteins

with

similar

monoubiquitination „consensus‟ sequences.9 A highly similar sequence - LVLRK was uncovered in the uncharacterized protein KIAA1794, which, upon further
examination, displayed approximately 40% sequence similarity within the regions
surrounding KIAA1794 K523 and FANCD2 K561.9 KIAA1794/FANCI was shown to
undergo DNA damage-inducible monoubiquitination,

and, importantly, this

monoubiquitination was dependent on both the presence and monoubiquitination of
FANCD2.9 Sims and colleagues subsequently sequenced all of the exons and intronexon boundaries of the FANCI gene for several FA patients of unassigned
complementation group with defective FANCD2 monoubiquitination. Biallelic
mutations in FANCI were uncovered in four patients. Patient EUFA592 expressed an
amino-terminal truncated FANCI as a result of a homozygous T to A transition in
exon 2 leading to the creation of a cryptic start site at M94.9 Patient F010191 was
compound heterozygous for FANCI mutations, with one allele encoding a R614X
variant and the other encoding FANCI R1299X. Only the latter variant was detectable
by immunoblotting. F010191 cells were defective for both FANCI and FANCD2

6

monoubiquitination indicating an important role for the extreme carboxy-terminus of
FANCI in the regulation of this posttranslational modification. Importantly, all FA-I
patients examined expressed some FANCI protein suggesting that FANCI null
mutations may lead to embryonic lethality.9

FA-D2 and FA-I Clinical Aspects
FA is a clinically heterogeneous disease characterized by a wide spectrum of
congenital abnormalities, a predisposition to develop early-onset progressive bone
marrow failure (BMF), and an increased risk of developing solid tumors in early
adulthood. The carrier frequency of FA was previously estimated at 1:300 with an
expected incidence rate of approximately 1:360,000.16 However, a more recent report
cites a higher carrier frequency of 1:156 - 1:209, leading to an expected incidence rate
of 1:130,000.17 A much higher carrier frequency of approximately 1:100 is found in
certain populations, including Spanish Romani, Ashkenazi Jews, and Afrikaaners; this
increase being attributed to the founder effect.17
It had previously been estimated that the FA-D2 complementation group
accounts for ~1-3% of all FA patients.18,

19

However, more recently it has been

reported that this complementation group accounts for approximately 6% of all FA
patients.20 Patients belonging to the FA-D2 complementation group display the
common FA congenital malformations including skin hypo- or hyper-pigmentation,
short stature, and microcephaly (Table 1).20-22 Importantly, these physical
abnormalities, along with skeletal irregularities such as radial ray deformities, often
allow for early clinical diagnosis. One notable difference between the FA-D2
7

8

complementation group and others is the penetrance of congenital abnormalities:
while it is estimated that ~30% of individuals with FA do not display any congenital
abnormality, every FA-D2 patient in one study exhibited a congenital defect.20
Distinct phenotypes have also been observed in Fancd2 knockout mice that are not
observed in Fanca, Fancc, or Fancg mutant mice.

23

Houghtaling and colleagues

discovered that Fancd2-/- mice have a high prevalence of micropthalmia, an increased
incidence of epithelial tumors, severe hypogonadism, as well as perinatal lethality. 23
In addition to the congenital abnormalities, an earlier mean age of onset of BMF is
observed for FA-D2 patients, compared to patients from all other FA complementation
groups - 4.5 y compared to 8.0 y.20,

24

Similar to that mentioned above for FA-I

patients, residual FANCD2 protein expression is detected in the vast majority of FAD2 patient cells, suggesting that only hypomorphic FANCD2 mutations are compatible
with viability. The majority of FANCD2 mutations detected among FA-D2 patients
are homozygous missense or compound heterozygous for a missense mutation and
nucleotide change affecting splicing, often leading to monoallelic expression of low
levels of both non- and monoubiquitinated FANCD2.1, 20
To date, only 12 patients from the FA-I complementation group have been
described, compared to 30 FA-D2 patients. Much less is known about FA-I patients‟
clinical manifestations, and this complementation group only accounts for an
estimated less than 1% of all FA cases.18 Of the few FA-I patients with available
clinical data, all have growth retardation (Table 2).8, 9 In addition, approximately 50%
of FA-I patients exhibit radial ray defects as well as both kidney and heart anomalies.
Furthermore, the age of onset of hematological manifestations among FA-I patients

9

10

varies widely, ranging from 1 - 8 y, and the average age of onset of BMF for the small
number of FA-I patients documented is 5.4 y.8 Of the limited FA-I population size
examined to date, to our knowledge no unique clinical manifestations have been
observed.

Domain Architecture and Structure of FANCD2 and FANCI
FANCD2 is a 1,451 amino acid protein with a molecular mass of 164 kDa. When
originally identified, FANCD2 was described as an orphan protein, as no recognizable
domains or enzymatic motifs were evident.1 To date, only four FANCD2
domains/motifs have been experimentally characterized (Figure 1A). The carboxyterminal EDGE motif, named for the single letter amino acid code, is not required for
FANCD2 monoubiquitination or nuclear foci formation. However, this motif is
necessary for complementation of the ICL-sensitivity of FA-D2 patient cells.25 An
interaction between FANCD2 and the major DNA processivity factor PCNA has also
been described.26 FANCD2 contains a highly conserved PIP-motif (PCNA-interacting
protein motif) which is necessary for the association of FANCD2 with PCNA
(proliferating cell nuclear antigen), and for efficient FANCD2 monoubiquitination,
nuclear foci formation and ICL repair, suggesting that PCNA may function as a
molecular scaffold to facilitate FANCD2 function.26 FANCD2 also harbors an aminoterminal CUE (coupling of ubiquitin conjugation to endoplasmic reticulum
degradation) ubiquitin-binding domain (UBD).27 The CUE domain adopts a triple helical configuration and mediates noncovalent ubiquitin binding. The CUE domain is
important for interaction with FANCI, for the retention of monoubiquitinated
11

Figure 1. Domain architecture and structure of FANCD2 and FANCI. (A)
Schematic of the FANCD2 protein indicating the amino-terminal NLS (nuclear
localization signal) domain (green), CUE (coupling of ubiquitin conjugation to
endoplasmic reticulum degradation) domain (maroon), PIP-box (PCNA-interacting
protein motif) (orange), and the carboxy-terminal EDGE motif (purple). Functionallycharacterized phosphorylation sites (teal) and K561 monoubiquitination site (yellow)
are indicated by small circles. (B) Schematic of the FANCI protein indicating the Leu
(leucine zipper) domain (light blue), ARM (armadillo repeat) domain (pink), and
carboxy-terminal EDGE motif (purple) and NLS domain (green). The S/TQ motif
(teal) and K523 site of monoubiquitination (yellow) are indicated by small circles. (C)
Mouse Fanci-Fancd2 heterodimer crystal structure represented as both surface and
ribbons with domains indicated. This structure was solved by the Pavletich group in
2011(PDB ID: 3S4W).35

12
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FANCD2 and FANCI in chromatin, and for efficient ICL repair.27 In addition, the
amino terminal 58 amino acids of FANCD2 harbors a nuclear localization signal
(NLS).28 This sequence is required for the efficient nuclear localization of both
FANCD2 and FANCI, and for their monoubiquitination and function in ICL repair.28
FANCI is a 1,328 amino acid protein with a molecular mass of 149 kDa
(Figure 1B). FANCI has an armadillo (ARM) repeat domain, which form superhelical
folds involved in mediating protein-protein interactions.10, 29 FANCI also possesses an
amino-terminal leucine zipper domain, a domain capable of mediating protein-protein
or DNA-protein interactions.30,

31

The FANCI leucine zipper domain does not bind

directly to DNA, but does contribute to FANCI protein stability.31 The conserved
carboxy-terminus of FANCI includes a putative EDGE motif and NLS, which have
been shown to enhance DNA binding and to promote the nuclear localization of
FANCI, respectively.31,

32

FANCI also possesses numerous S/TQ motifs, known

ATM/ATR phosphorylation consensus sites, and mass spectrometry revealed that at
least five of these sites are phosphorylated in human and mouse FANCI. 15, 33, 34 The
alignment of human and chicken FANCI sequences revealed that eight S/TQ motifs
are highly conserved, with six of these motifs clustering proximal to K523, the site of
FANCI monoubiquitination.9, 10, 33
Importantly, the 3.4Å crystal structure of the murine Fancd2-Fanci heterodimer
(ID2) was recently solved by the Pavletich laboratory. While this structure continues
to be a major resource for FA researchers, it is important to recognize that structural
information remains lacking for several peptide stretches of both proteins.35 Fancd2
and Fanci are structurally highly similar and consist largely of antiparallel -helices
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that form -superhelical structures referred to as solenoids. Fancd2 and Fanci fold
into back-to-back, inverted saxophone-like structures with trough-like partially open
ends (Figure 1C). Multiple positively charged grooves within these troughs are
capable of accommodating single and double-stranded DNA. The sites of
monoubiquitination are located in the ID2 interface within solvent accessible tunnels.
However, these tunnels are predicted to be too small to accommodate the ubiquitin
ligase machinery, raising challenging questions about the temporal, kinetic, and spatial
aspects of FANCD2 and FANCI monoubiquitination.35

FANCD2 and FANCI Monoubiquitination
Protein ubiquitination is a multi-step post-translational modification that results in the
covalent attachment of a single ubiquitin molecule (monoubiquitination) or chain of
linked ubiquitin molecules (polyubiquitination) to a lysine residue on a substrate
protein. Mono- and poly-ubiquitination signal a wide range of cellular instructions, the
former being most typically associated with the targeting of proteins to specific subcellular localizations, while the canonical role of the latter is to target proteins for
degradation by the proteasome.36,

37

In the general process of ubiquitination, an E1

ubiquitin-activating enzyme activates ubiquitin by forming a thioester bond between a
catalytic C of E1 and the carboxy-terminal G76 of ubiquitin. Ubiquitin is then
transferred from the E1 to an active site C of an E2 ubiquitin-conjugating enzyme.
Ubiquitin can be further transferred to the catalytic site of a HECT (homologous to
E6-AP carboxy terminus) domain-containing E3 ubiquitin ligase, and then
subsequently transferred to a target K on the substrate. Alternatively, through the
15

action of a RING (really interesting new gene) domain-containing E3 ubiquitin ligase,
ubiquitin is transferred directly from the E2 to the substrate. The human genome
encodes two E1 ubiquitin-activating enzymes, ~40 E2 ubiquitin-conjugating enzymes,
and >600 E3 ubiquitin ligases.38
As mentioned above, when the FANCD2 protein was first characterized by
Garcia-Higuera and colleagues in 2001, two isoforms of FANCD2 were detected by
immunoblotting; a short form approximately 164 kDa and a longer form
approximately 173 kDa.3 The latter isoform was determined to represent FANCD2
covalently linked to a single ubiquitin polypeptide on K561.3 Similar to FANCD2, a
slower migrating isoform of FANCI was also detected by immunoblotting, following
treatment of cells with DNA damaging agents.9 This slower migrating FANCI isoform
was subsequently determined to represent FANCI monoubiquitinated on K523.9,

10

The monoubiquitination of FANCD2 and FANCI is required for their assembly into
discrete nuclear foci, where they co-localize with several proteins including the
protein product of one of the major breast and ovarian cancer susceptibility genes
BRCA1.3,

9, 10

This seminal finding provided an important clue as to a potential

function for FANCD2, FANCI, and the FA-BRCA pathway, as BRCA1 had
previously been determined to play a key role in DNA repair by homologous
recombination (HR).39-41 HR is an error-free and conservative DNA repair pathway
that utilizes an intact homologous template, such as a sister chromatid or homologous
chromosome, to repair DNA damage.42 The ability of FANCD2 and FANCI to
promote error-free HR repair was assessed using the DR-GFP HR reporter assay
system developed by the Jasin laboratory.43,
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This reporter assay comprises two

differentially mutated nonfunctional GFP genes oriented in tandem, and separated by
a drug selection marker. One GFP gene is interrupted with the rare 18-bp I-Sce I
restriction endonuclease recognition sequence, while the other is an 812-bp internal
fragment. Following induction of a DSB with the I-Sce I endonuclease, a gene
conversion HR event results in the expression of GFP, which can be assayed by flow
cytometry or fluorescence microscopy.43 Knockdown of either FANCD2 or FANCI,
as well as mutation of FANCD2 K561 or FANCI K523, which precludes the covalent
attachment of ubiquitin, leads to decreased HR efficiency.9, 10, 44 Taken together, this
data strongly suggests that monoubiquitinated FANCI and FANCD2 function
cooperatively to promote error-free HR repair. Importantly, FANCD2 and FANCI
monoubiquitination and nuclear foci formation are interdependent.9,
siRNA-mediated

depletion

of

FANCI

results

in

10

For example,

decreased

FANCD2

monoubiquitination and nuclear foci formation, as well as a reduction in steady state
levels of FANCD2.9,

10

between

and

FANCD2

These findings were suggestive of a physical interaction
FANCI,

and

indeed

this

was

verified

by

co-

immunoprecipitation studies as well as by co-crystallization of the murine ID2
heterodimer.10,

35

Mutation of FANCD2 K561 renders this protein incompetent for

nuclear foci formation, and abrogates its ability to rescue the ICL hypersensitivity of
FA-D2 patient cells. Mutation of FANCI K523 also precludes its assembly into
nuclear foci.9,

10

However, somewhat surprisingly, in contrast to FANCD2 K561,

mutation of FANCI K523 does not overtly affect its function in ICL repair.3, 9, 10, 33 In
vitro studies have also revealed that mutation of FANCD2 K561 leads to impaired

17

FANCI monoubiquitination, whereas mutation of FANCI K523 has little effect on the
monoubiquitination of FANCD2.45
The E2 ubiquitin-conjugating enzyme and E3 ubiquitin ligase for FANCD2
and FANCI monoubiquitination are UBE2T and the RING domain-containing
FANCL, respectively.46, 47 Biallelic mutations in the FANCL gene underlie the FA-L
complementation group, however, FA patient-derived mutations in UBE2T have yet to
be uncovered.46,

47

In addition to UBE2T and FANCL, the monoubiquitination of

FANCD2 and FANCI requires the assembly of the FA core complex, comprising
FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, and FANCM, as well as
numerous accessory proteins including FAAP20, FAAP24, FAAP100, MHF1, and
MHF2.48-53 The precise roles of these ancillary proteins in FANCD2/FANCI
monoubiquitination remain to be determined. Indeed, in vitro FANCD2/FANCI
monoubiquitination reactions have been reconstituted with FANCL in the absence of
these FA core complex components.54-56 Recent studies have identified three
functional modules within the FA core complex: the FANCB-FANCL-FAAP100
module, which provides the critical catalytic activity, and the FANCA-FANCGFAAP20 and FANCC-FANCE-FANCF modules, which independently promote the
recruitment of the core complex to chromatin.57, 58 Accordingly, using isogenic single
and double mutants of the HCT116 colorectal carcinoma cell line, Huang et al.
established that FANCD2/I monoubiquitination is completely abrogated in the absence
of FANCB, FANCL, or FAAP100, and only partially abrogated in the absence of
FANCA, FANCG, FANCE, or FAAP20.57 Furthermore, in contrast to FANCD2, the
purified FA core complex fails to robustly promote the monoubiquitination of FANCI
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in the absence or presence of DNA.58 To gain further insight into the relationship
between the FA core complex members and FANCD2/I monoubiquitination, it is
useful to draw comparisons with other large multi-subunit ubiquitin ligase protein
complexes, such as the Skp1/Cullin/F-box protein complex (SCF) (Figure 2).59 SCF,
along with the anaphase-promoting complex or cyclosome (APC/C), plays an intricate
and critical role in cell-cycle regulation.60 The F-box protein of the SCF complex
functions in substrate recognition and recruitment.59 A good candidate for an FApathway protein analogous to the SCF F-box protein is FANCE, a FA core complex
member that has been demonstrated to interact with FANCC, FANCF, and FANCD2,
thereby bridging the core ubiquitin ligase machinery and the substrate.61 The FANCEFAND2 interaction, via FANCE F522, is critical for efficient FANCD2
monoubiquitination and ICL repair.62 The Cullin protein functions as a molecular
scaffold for the SCF complex, bridging the catalytic RING finger subunit RBX1 to the
adaptor and F-box proteins. The FANCA protein, with a molecular mass of 163 kDa,
may play a similar structural role in the FA-BRCA pathway. FANCA interacts with
FANCC, FANCG, and FAAP20.12, 57, 58, 63, 64 The Skp1 protein of the SCF complex
functions as an adaptor between the Cullin protein and the F-box protein.65 FANCC
interacts with FANCA, FANCE, and FANCF and thus represents a strong candidate
Skp1 analog.57, 58, 61 FANCM is present in very low abundance in the native FA core
complex, consistent with its role in replication fork remodeling and chromatin loading
of the core complex.58,

66-68

The core complex members FANCM, FANCG, and

FANCF do not appear to have analogous SCF components. FANCL is analogous to
the SCF E3 ubiquitin ligase RBX1. As mentioned above, FANCL, FANCB, and
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Figure 2. Comparison of the SCF multi-subunit ubiquitin ligase protein complex
and the FA core complex. (A) The Skp1/Cullin/F-box protein (SCF) complex
includes the Cullin protein, which acts as a scaffold to bridge the catalytic E3 ubiquitin
ligase RBX1 to the adaptor protein Skp1, and the F-box protein.59 The F-box protein
recognizes and recruits the target protein for ubiquitination by the E2 ubiquitinconjugating enzyme, UBC. (B) We propose that the FANCA protein is structurally
analogous to Cullin, and may link the E3 ubiquitin ligase FANCL with the putative
adaptor protein FANCC. FANCC has been shown to interact with both FANCA and
FANCE, indicating that it may function analogously to Skp1.61 FANCE may be
analogous to the F-box protein. FANCE is known to interact directly with FANCD2
and may facilitate its monoubiquitination of FANCL and UBE2T.62
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FAAP100 comprise the E3 monoubiquitin ligase catalytic module.57,

58

FANCL and RBX1 are both RING E3 ubiquitin ligases, with the RING domain
facilitating recruitment of the E2 ubiquitin-conjugating enzyme, UBE2T in the case of
the FA-BRCA pathway and UBC3, UBC4, or UBC5 for SCF.46, 65, 69 FANCL binds to
FANCD2 via its DRWD domain, and to UBE2T via its RING domain, to facilitate
monoubiquitination.69, 70

Ubiquitination: Mono- versus PolyTo date, only the monoubiquitination of FANCD2 has been observed, begging the
question;

how

is

monoubiquitinated

FANCD2

restricted

from

being

polyubiquitinated? Insights into this question can be gained from extensive studies of
regulators of endocytosis. Many endocytic proteins are monoubiquitinated in a process
referred to as coupled monoubiquitination, whereby substrate recognition and
ubiquitination are regulated, at least in part, through noncovalent interactions between
ubiquitin and substrate ubiquitin-binding domains (UBDs). One such example is
EPS15 (epidermal growth factor receptor pathway substrate 15), an important
regulator of the endocytosis of ligand-inducible receptors of the receptor tyrosine
kinase (RTK) family, in particular EGFR.71 EPS15 is monoubiquitinated by the
NEDD4 HECT E3 ubiquitin ligase and by the Parkin RING E3 ubiquitin ligase.
EPS15 harbors two ubiquitin-interacting motifs (UIMs) in its carboxy-terminus that
are critical for its regulation. One proposed model for why EPS15 is solely
monoubiquitinated is that once ubiquitinated, EPS15 undergoes an intramolecular
rearrangement enabling covalently attached ubiquitin to engage in a noncovalent

22

interaction with one of its two carboxy-terminal UIMs, generating a closed
conformation refractory to further ubiquitination.72,

73

The crystal structure of the

murine ID2 heterodimer has revealed that the mouse Fancd2 K559 and Fanci K522
sites of monoubiquitination are buried within the ID2 interface. A solvent accessible
tunnel adjacent to these sites is predicted to be too small to accommodate UBE2T,
suggesting that monoubiquitination either precedes heterodimerization or occurs
subsequent to ID2 dissociation. Similar to the EPS15 UIM, one possibility is that ID2
heterodimerization occurs following monoubiquitination, and that the ID2 heterodimer
is stabilized through a noncovalent interaction between monoubiquitin covalently
linked to FANCI K523 and the FANCD2 CUE domain, and quite possibly a reciprocal
interaction between monoubiquitinated FANCD2 K561 and an UBD in the carboxyterminus of FANCI (Figure 3A).27 Thus, FANCD2 and FANCI might be shielded
from further ubiquitination via intermolecular association. It is also possible that
monoubiquitination promotes an intramolecular association between ubiquitin
covalently attached to K561 and the amino-terminal CUE domain,27 potentially
blocking the ubiquitin on K561 from further ubiquitination, similar to that for EPS15
(Figure 3B). The latter model would more closely align with recent findings from the
Sobeck laboratory indicating that activation of the FA-BRCA pathway coincides with
dissociation of FANCD2 and FANCI.74 ID2 dissociation is triggered by ATM/ATRmediated phosphorylation of a cluster of at least six FANCI SQ/TQ motifs, and is
followed by the monoubiquitination of FANCD2, see below.33, 74
The NEDD4 E3 ubiquitin ligase can mono- and polyubiquitinate substrates,
and the balance between these two posttranslational modifications is determined, at
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Figure 3. Models for FANCD2 and FANCI monoubiquitination. The schematics
depict several potential outcomes upon monoubiquitination of FANCD2 and FANCI,
which would preclude further ubiquitination. (A) The ID2 heterodimer inactivation
model. Following monoubiquitination, ID2 heterodimerization occurs and is stabilized
through a noncovalent interaction between monoubiquitin covalently linked to FANCI
K523 and the FANCD2 CUE domain. There is also possibly a reciprocal interaction
between monoubiquitinated FANCD2 K561 and an UBD in the carboxy-terminus of
FANCI, shielding FANCD2 from further ubiquitination. (B) The FANCD2 selfinactivation model. Monoubiquitination could promote an intramolecular association
between ubiquitin covalently attached to K561 and the amino-terminal CUE domain,
resulting in a closed conformation. (C) The E3 ubiquitin ligase dissociation model.
Once FANCL is autoubiquitinated, the ubiquitin moiety may interact noncovalently
with the CUE domain on FANCD2 enabling monoubiquitination of FANCD2 on
K561. This interaction is predicted to be weak and short-lived, leading to rapid
dissociation

of

FANCL

and

FANCD2,
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precluding

further

ubiquitination.
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least in part, by the nature of the enzyme-substrate interaction. The tryptophantryptophan (WW) motif of NEDD4 can interact with relatively high affinity to a
substrate PPxY (where x is any amino acid) motif, leading to substrate
polyubiquitination.75, 76 EPS15 lacks a PPxY motif and instead interacts with NEDD4
via a weak noncovalent interaction between ubiquitin covalently conjugated to
NEDD4 and one of its carboxy-terminal UIMs.77, 78 Similarly, EPS15 interacts with
the Parkin RING E3 ubiquitin ligase via a weak interaction between an ubiquitin-like
domain (UbL) in Parkin and one of its UIMs.79 Previous studies have indicated that
the FANCL E3 ubiquitin ligase, as well as the UBE2T E2 ubiquitin-conjugating
enzyme, undergoes autoubiquitination.54, 80 Therefore, the FANCD2 CUE domain may
interact with ubiquitin conjugated to FANCL (or UBE2T) and, because of the weak
nature of this interaction, FANCD2 and FANCL may rapidly dissociate following
ubiquitination, precluding further ubiquitination (Figure 3C).
Another major factor influencing mono- versus poly-ubiquitination is the
nature of the E2 ubiquitin-conjugating enzyme. There are ~40 E2 ubiquitinconjugating enzymes encoded by the human genome, 28 of which are classified as
monoubiquitinating E2s. The FANCD2/I E2 ubiquitin-conjugating enzyme UBE2T is
classified as a monoubiquitinating E2.46,

54, 56, 80

Several other E2s function as

polyubiquitinating E2s and display ubiquitin linkage-specificity. For example,
UBE2G1, UBE2G2, UBE2K, UBE2R1, and UBE2R2 promote the assembly of K48linked polyubiquitin chains, while UBE2S and UBE2N promote the assembly of K11and K63-linked polyubiquitin chains, respectively.81 In the case of UBE2N, K63linked polyubiquitin chain assembly is facilitated by the cofactor proteins UBE2V1
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and UBE2V2, which structurally align K63 of the acceptor ubiquitin toward the active
site C of UBE2N.82, 83 Thus, the monoubiquitination fate of FANCD2 and FANCI may
simply be determined by the mechanistic nature of UBE2T. Nevertheless, much
remains to be learned about the mechanism, structure, and regulation of UBE2T.
Lastly, the concentration of an E3 ubiquitin ligase relative to the concentration
of its substrate has also been shown to play an important role in determining if a
protein is monoubiquitinated or polyubiquitinated. One example of this mechanism of
regulation applies to the ubiquitination of the p53 tumor suppressor protein by its E3
ubiquitin ligase MDM2: When levels of MDM2 are low, p53 is largely
monoubiquitinated. Conversely, when levels of MDM2 are high, p53 is predominantly
polyubiquitinated.84 Likewise, it is plausible that the cellular concentration of FANCL
is

sufficient

for

FANCD2/I

monoubiquitination

only,

precluding

further

ubiquitination.

FANCD2 and FANCI Deubiquitination
The site-specific monoubiquitination of FANCD2 and FANCI is a reversible process.
The deubiquitination of monoubiquitinated FANCD2 and FANCI is mediated by
ubiquitin-specific protease 1 (USP1). This important function for USP1 was
uncovered in a DUB (deubiquitinating enzyme) gene family RNA interference library
screen, whereby knockdown of USP1 resulted in a significant increase in
monoubiquitinated FANCD2.85 Deletion of murine Usp1 results in increased perinatal
lethality, male infertility, and an FA phenotype.86 Usp1-/- mouse embryonic fibroblasts
(MEFs) exhibit elevated levels of Fancd2 monoubiquitination and impaired Fancd2
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nuclear foci formation and are defective in HR repair.86 USP1 is activated upon
formation of a complex with the UAF1 (USP1 associated factor-1) protein.87 The
amino-terminus of UAF1 has a WD40 domain, which binds and activates USP1, while
the carboxy-terminus contains two SUMO-like domains (SLD1 and SLD2) that
mediate substrate binding.87,

88

FANCI harbors a highly conserved SUMO-like

domain-interacting motif (SLIM) that has been shown to interact with SLD2 of UAF1,
targeting USP1/UAF1 to the ID2 complex.88 USP1/UAF1 activity is tightly regulated:
upon exposure to UV irradiation, USP1 undergoes inhibitory autocleavage.89 The
carboxy-terminal fragment of autocleaved USP1 is subsequently degraded by the R/Nend rule pathway, leading to the effective elimination of deubiquitinating activity.90
The USP1 gene is also transcriptionally repressed upon cellular exposure to DNA
damaging agents, a process that requires the function of the p21 cyclin-dependent
kinase inhibitor.87,

91

Both negative regulatory mechanisms facilitate the timely

accumulation of monoubiquitinated FANCD2 and FANCI following the induction of
DNA damage.89

FANCD2 Phosphorylation
The FANCD2 protein is also subject to posttranslational modification by
phosphorylation. The ATM kinase is a member of the phosphatidylinositol-3-OHkinase-like family of protein kinases (PIKK). Bilallelic mutations in the ATM gene
cause the autosomal recessive disorder Ataxia- telangiectasia (AT).92 AT is clinically
characterized by progressive cerebellar ataxia, telangiectasias, immune defects, and
increased susceptibility to hematologic cancers of B and T cell origin, as well as
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central nervous system tumors.93, 94 The ATM kinase plays a major coordinating role
in the cellular response to DNA DSBs and phosphorylates multiple substrates to halt
cell cycle progression and initiate DNA repair. For example, the ATM kinase
phosphorylates T68 of the CHK2 kinase following exposure to ionizing radiation (IR)
to initiate cell cycle arrest at the G1-S boundary.95 In 2002, Taniguchi and colleagues
discovered that ATM phosphorylates FANCD2 on S222, S1401, S1404, and S1418 in
response to IR exposure.96 Phosphorylation of FANCD2 S222 is required for the
establishment of the IR-inducible S phase checkpoint, an ability to pause DNA
synthesis in the presence of chromosomal DSBs.97 However, ATM-mediated
FANCD2 S222 phosphorylation is dispensable for FANCD2 monoubiquitination,
nuclear foci formation, and ICL resistance.96
An important role for the ATR kinase in the regulation of FANCD2 has also
been established.98, 99 While ATM primarily responds to DNA DSBs, ATR is a major
regulator of the DNA replication checkpoint, primarily responding to agents that
disrupt DNA replication, e.g. hydroxyurea, an inhibitor of deoxyribonucleotide
reductase, aphidicolin (APH), a processive DNA polymerase inhibitor, and UV
irradiation, which promotes the formation of cyclobutane pyrimidine dimers.100,

101

Mutations in ATR underlie Seckel syndrome (SCKL1) a rare autosomal recessive
disorder characterized by severe growth retardation, short stature, microcephaly,
mental retardation, and increased risk for acute myeloid leukemia (AML),
myelodysplasia (MDS), and aplastic anemia, similar to FA.102-104 Following exposure
to DNA crosslinking agents, ATR and FANCD2 co-localize in nuclear foci.98, 105 ATR
also promotes efficient DNA damage-inducible FANCD2 monoubiquitination and
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nuclear foci formation.98 Accordingly, similar to FA patient cells, ATR-deficient
SCKL1 patient cells exhibit increased chromosome aberrations, including radial
formations, following exposure to MMC.98, 104 The D‟Andrea laboratory established
that ATR phosphorylates FANCD2 on T691 and S717 in vitro and in vivo.98,

99

A

FANCD2-T691A/S717A double mutant fails to undergo efficient DNA damageinducible monoubiquitination and fails to correct the MMC hypersensitivity of FA-D2
patient cells.99 How phosphorylation of these two sites promotes FANCD2
monoubiquitination remains unclear. Phosphorylated T691 and S717 may stimulate
interaction with the core complex or with FANCL or UBE2T, promoting
monoubiquitination. Alternatively, phosphorylation may promote dissociation from
FANCI, allowing access to K561, similar to that described for FANCI, see below.
Phosphorylation could also promote the interaction of FANCD2 with DNA in
chromatin,

which

has

been

shown

to

lead

to

increased

efficiency

of

monoubiquitination.56, 106

FANCI Phosphorylation
FANCI was originally identified as an ATM/ATR substrate in a large-scale SILAC
(stable isotope labeling with amino acids in cell culture) proteomics screen.15 As
described above, six S/TQ motifs are positioned proximal to K523, the sites of
monoubiquitination. These S/TQ sites become phosphorylated in the absence of prior
monoubiquitination, indicating that this posttranslational modification acts upstream
of monoubiquitination.33 Importantly, mutation of these S/TQ sites results in
abrogation of FANCI and FANCD2 monoubiquitination and nuclear foci formation,33
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indicating that phosphorylation of the FANCI S/TQ cluster functions as a molecular
switch to activate the FA-BRCA pathway. However, the underlying molecular
mechanism remains unclear. Recently, it has been suggested that activation of the
pathway coincides with disassociation of the ID2 heterodimer, and that ID2
disassociation is triggered by ATM/ATR-mediated phosphorylation of the S/TQ
cluster.106 Using cell-free Xenopus laevis egg extracts, Sareen and colleagues
demonstrated that a FANCI S/TQ cluster phosphorylation-dead mutant failed to
dissociate from FANCD2 and failed to undergo monoubiquitination. Conversely, a
phosphorylation-mimetic mutant failed to associate with FANCD2 and exhibited
increased monoubiquitination.106 Taken together, these findings indicate that
phosphorylation of FANCI at the conserved S/TQ cluster is a key mechanism in the
activation of the FA-BRCA pathway. The introduction of a cluster of negatively
charged phosphate groups may result in a localized charge repulsion that promotes
ID2 disassociation, enabling access of the previously occluded ubiquitin ligase
machinery.

FANCD2 and FANCI Function
Replisome Surveillance
Early studies indicated that, in addition to being monoubiquitinated following
exposure to DNA damaging agents, FANCD2 and FANCI monoubiquitination also
occurs during unperturbed cell cycle progression. In addition, monoubiquitinated
FANCD2 co-localizes with BRCA1 and RAD51 in nuclear foci during S phase.97
These findings strongly suggested that monoubiquitinated FANCD2 might play an
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important role in maintaining genome stability during the process of DNA
replication.10, 97 Accordingly, the FANCD2 and FANCA proteins are required for the
maintenance of common chromosomal fragile site (CFS) stability.107 CFS are
chromosomal loci that are prone to breakage when cells are cultured under conditions
of DNA replication stress, for example following treatment with low concentrations of
the DNA polymerase inhibitor APH.108 CFSs are hot spots for sister chromatid
exchanges (SCE), chromosomal translocations, and viral integration, and are
frequently rearranged or deleted in cancer.109 The physical localization of FANCD2
and FANCI to FRA3B and FRA16D, the most frequently expressed CFSs, has also
been demonstrated.110 Combined immunofluorescence microscopy and FISH analysis
of metaphase chromosomes revealed the presence of paired FANCD2/I-stained CFSs
on sister chromatids linked by BLM helicase-associated ultra-fine DNA bridges
(UFBs).110, 111 These paired FANCD2/I sister foci form during S phase and persist into
mitosis, and their presence strongly suggest that FANCD2 and FANCI participate in
the resolution of stalled or collapsed DNA replication forks that recurrently arise at
particularly unstable genomic loci.107, 110, 111 In further support of an important role for
FANCD2 in the resolution of stalled or collapsed replication forks, Fancd2-/- MEFs
are ICL hypersensitive yet do not display increased sensitivity to IR.23 Consistent with
a role for the FA-BRCA pathway in the DNA replication stress response, FANCD2
has been shown to interact with several components of the DNA replisome. For
example, as mentioned earlier, FANCD2 interacts with the DNA polymerase
processivity factor PCNA, via a conserved PIP-box, and this interaction is necessary
for efficient FANCD2 monoubiquitination and ICL repair.26 In addition, using a
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method called iPOND (isolation of proteins on nascent DNA), the Cortez group
recently discovered that FANCD2 and FANCI, in addition to ATR, MRE11 and other
proteins, are highly enriched at stalled and collapsed replication forks following
depletion of deoxyribonucleotide pools.112 Interestingly, FANCI, and not FANCD2,
was also shown to accumulate at active replication forks prior to fork staling,
suggesting common and independent functions for these proteins.

112

In addition, the

Vaziri group has recently shown that FANCD2 is necessary for efficient initiation of
DNA replication in primary human fibroblasts.113 An unbiased proteomics screen of
chromatin-bound FANCD2 immune complexes revealed that FANCD2 physically
associates with the minichromosome maintenance 2-7 (MCM2-MCM7) replicative
helicases.114, 115 FANCD2 interacts with MCM2-MCM7 in response to ATR-mediated
DNA replication stress signaling independently of the core FA complex and
monoubiquitination.115 In the absence of FANCD2, replication forks stall
stochastically and primary cells exhibit increased senescence, indicating that FANCD2
is required for replication fork progression.115 Schlacher and colleagues also showed
that FANCD2 is necessary to protect stalled replication forks from MRE11-mediated
degradation, and that fork protection in the absence of FANCD2 can be rescued by
RAD51.116 Moreover, it was recently discovered that FANCD2, in cooperation with
BRCA1 and MRE11, recruits and interacts with CtIP (CtBP-interacting protein) at
stalled replication forks to promote replication restart.117,

118

CtIP was originally

identified on the basis of its ability to bind to CtBP (C-terminal binding protein), a
transcriptional co-repressor.118 However, several recent studies have established that
CtIP interacts with the MRN (MRE11/RAD50/NBS1) complex and BRCA1 and
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facilitates the DNA strand resection step of HR repair.118-121 This evidence supports a
key role for FANCD2 and FANCI in coordinating the recruitment of HR proteins to
sites of stalled replication forks, enabling timely replication fork resolution and
progression.
In addition to being directly regulated by the FANCL-UBE2T ubiquitin ligase
machinery, several studies have established that FANCD2/I monoubiquitination is
indirectly regulated by the RAD18-RAD6 E3/E2-ubiquitin ligase complex.122-126
RAD18-RAD6 catalyzes the monoubiquitination of PCNA on K164, a molecular
event necessary for DNA polymerase switching during translesion DNA synthesis
(TLS).127, 128 TLS polymerases possess larger active sites and exhibit reduced fidelity,
and have the ability to catalyze DNA polymerization opposite DNA templates
harboring aberrantly modified nucleobases.129 RAD18 and FANCD2, as well as
FANCL, function epistatically in the cellular ICL response.122, 126 Genetic disruption
of RAD18 or RAD18 depletion via siRNA leads to decreased ICL-induced FANCD2/I
monoubiquitination and chromatin binding.122-126 Furthermore, RAD18-RAD6
mediated monoubiquitination of PCNA on K164 is necessary for efficient FANCD2
monoubiquitination.122 FANCL was also shown to bind to PCNA directly and PCNA
K164 monoubiquitination was shown to be required for FANCL chromatin loading.122
While the molecular mechanism underlying this regulation remains unclear, these
findings suggest that the FANCL-UBE2T and RAD18-RAD6 ubiquitin ligases
cooperatively regulate FANCD2/I and PCNA monoubiquitination, respectively, to
facilitate the coordinated recruitment of HR and TLS factors to stalled or collapsed
replication forks.
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Independent Functions of FANCD2 and FANCI
BLM Complex Chromatin Assembly
Since the discovery of FANCI, it has generally been accepted that FANCD2 and
FANCI function cooperatively in the resolution of ICLs. However, several recent
studies have suggested independent functions for these proteins. For example, it has
recently been determined that FANCD2, and not FANCI, is an important regulator of
the recruitment of the BLM helicase to chromatin.130 Biallelic mutations in the BLM
gene underlie Bloom syndrome (BS), a rare recessive disorder characterized by growth
retardation, sunlight sensitivity, telangiectasia, hypo- or hyper-pigmentation of the
skin, and increased susceptibility to hematologic cancers.131 The BLM helicase is a
member of the RecQ family of helicases, which also includes the WRN and RECQ4
proteins, and possesses ATP-dependent 3‟-5‟ DNA helicase activity.132 Similar to FA
patient cells, BS patient cells are hypersensitive to the cytotoxic effects of DNA
crosslinking agents as well as agents that inhibit DNA replication.133, 134 In addition,
FANCD2 and BLM co-localize in nuclear foci following exposure to DNA damaging
agents.134 Pichierri and colleagues established that the DNA damage-inducible
phosphorylation of BLM and its ability to assemble into nuclear foci are compromised
in FA-C and FA-G patient cells.134 In contrast, FANCD2 monoubiquitination and
nuclear foci formation, as well as the DNA damage-inducible chromatin localization
of FANCA and FANCC, are intact in BS patient cells.134 Similarly, using Xenopus egg
extracts, Chaudhury et al recently showed that immunodepletion of both FANCD2
and FANCI leads to a failure of the BLM helicase, and its binding partners TOP3a,
RMI1, RM2, and RPA1-3, to associate with chromatin. Notably, FANCD2 alone is
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sufficient to rescue this defect.130 Furthermore, neither FANCI nor FANCD2
monoubiquitination are required to promote BLM complex chromatin assembly,
indicating that this function is monoubiquitination and FANCI-independent.130

Nucleosome Assembly Activity
FANCD2 was recently identified in a proteomics screen of histone H3/H4-interacting
proteins.135 Recombinant FANCD2 was subsequently confirmed to bind to H3/H4 in
vitro.135 These findings suggested that FANCD2 might play an active role in
chromatin dynamics and/or reorganization. Indeed, using a topological assay and a
nucleosome assembly assay, FANCD2 was shown to promote nucleosome assembly
to an extent comparable to that of the known nucleosome assembly protein Nap1.
Similar to the promotion of BLM complex chromatin localization, FANCD2 histone
binding

and

nucleosome

assembly

activity

appear

to

be

FANCI

and

monoubiquitination-independent.135 However, while FANCI fails to promote
nucleosome assembly by itself, it can stimulate FANCD2-mediated nucleosome
assembly at low FANCD2 concentrations. These results suggest that the ID2 complex
may promote chromatin reorganization during ICL repair. Consistent with this
hypothesis, FANCD2 was previously discovered to interact with the 60 kDa Tatinteractive protein (TIP60) chromatin remodeling acetyltransferase and menin, a
chromatin remodeling tumor suppressor.136,

137

Depletion of TIP60 using siRNA

sensitizes cells to ICL cytotoxicity.137 TIP60 is a subunit of the NuA4 chromatin
remodeling complex, which comprises multiple enzymatic subunits including TIP60,
the p400 motor ATPase, and the RUVBL1 and RUVBL2 helicase-like proteins.138
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Upon DSB generation, TIP60 is rapidly recruited to sites of damage where it
acetylates multiple substrates including H2A, H4, p53, and ATM.139-142 Menin has
also been shown to function in chromatin remodeling, and DNA repair.136, 143, 144 Cells
lacking menin are more sensitive to DNA damage and the interaction between
FANCD2 and menin is increased following exposure to IR.136 Collectively, these
findings suggest that FANCD2 may function in a chromatin remodeling capacity
during the early stages of ICL repair.

FANCD2: Recruitment of Nucleases
Several recent studies have provided important mechanistic insight into the function of
monoubiquitinated FANCD2 in ICL repair. The previously uncharacterized
KIAA1018 protein was simultaneously identified by several groups as a FANCD2interacting partner and an important cellular determinant of ICL repair efficiency.145147

The Jiricny group identified KIAA1018 as a component of the mismatch repair

MLH1 and PMS2 interactomes. This protein was predicted to harbor an aminoterminal UBZ (ubiquitin-binding zinc finger) UBD and a carboxy-terminal PDD/E(X)K-type nuclease domain.146 Similarly, the Huang and Rouse groups identified
KIAA1018 on the basis of its UBZ domain and a VRR_nuc (virus-type replicationrepair nuclease) domain, which contains a motif frequently found in bacterial and
bacteriophage restriction nucleases.145,

148

Importantly, UBZ domains have been

uncovered in several DNA damage response proteins, including RAD18 and DNA
polymerase κ (POL κ).149,

150

In another approach, Smogorzewska and colleagues

discovered KIAA1018 in an unbiased genome-wide shRNA screen of proteins
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necessary for efficient ICL repair.147 KIAA1018 was found to co-localize with
FANCD2 in nuclear foci following ICL exposure and to interact with FANCD2 via
co-immunoprecipitation analysis, and was hence renamed FAN1 (FANCD2associated nuclease 1).145-148 FAN1 was shown to display 5‟-3‟ exonuclease activity
and

structure-specific

endonuclease

activity,

preferentially

toward

5‟

flap

structures.145-148 Furthermore, the FAN1 UBZ domain was shown to interact
noncovalently with monoubiquitin conjugated to FANCD2 K561. The FAN1 UBZ
domain and the monoubiquitination of FANCD2 were shown to be required for the
recruitment of FAN1 to sites of DNA damage, and for efficient ICL repair.145 While
FAN1 mutations have yet to be uncovered in FA patients, mutations in FAN1 have
been identified as a cause of karyomegalic interstitial nephritis, a chronic kidney
disease.151
Mutations in the SLX4 gene were recently uncovered in FA complementation
group P.152-154 FANCP/SLX4 is a ~200 kDa multidomain protein that, similar to
FAN1, harbors an amino-terminal UBZ domain.155 FANCP/SLX4 functions as a
molecular platform to coordinate the activities of the structure-specific endonucleases
XPF-ERCC1, MUS81-EME1, and SLX1, with XPF-ERCC1 playing a major role in
ICL repair, and MUS81-EME1 and SLX1 playing less critical roles.156-160 Similar to
FAN1 and FANCD2, FANCP/SLX4 and FANCD2 co-localize in nuclear foci and coimmunoprecipitate.154 While Yamamoto and colleagues established that the
FANCP/SLX4 UBZ domain and the monoubiquitination of FANCD2 are required for
FANCP/SLX4 targeting to nuclear foci, a recent report has contradicted these findings
and

shown

that

SLX4

recruitment
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occurs

independent

of

FANCD2

monoubiquitination.154,

161

Taken together, these findings suggest that one major

function for chromatin-bound monoubiquitinated FANCD2 may be the recruitment of
structure-specific endonucleases that mediate key incision steps during the process of
ICL repair.162

FANCD2 and FANCI: DNA Binding
Several studies have established that FANCD2 and FANCI physically bind to DNA.
Using FANCD2 purified from baculovirus-infected SF9 insect cells, the Parvin group
originally determined that full-length FANCD2 binds to dsDNA and Holliday
junctions (HJs), quadruplex heteroduplex DNA intermediates that arise during HR.163
Similarly, the Zhang group purified full-length FANCI and demonstrated that it can
bind to multiple DNA substrates, including HJs, dsDNA, ssDNA, and flap structures,
without any apparent structural preference.31 Longerich et al also demonstrated that
purified FANCI is capable of binding to dsDNA, ssDNA, and HJs.80 Importantly,
however, co-purified ID2 displayed a much lower affinity for dsDNA and ssDNA, yet
maintained a robust binding activity towards HJs and various branched DNA
structures.31 Consistent with these findings, the Pavletich group described the structure
of co-crystals of FANCI bound to splayed Y DNA at a resolution of 7.8 Å.35 Based on
this structure and the structural homology between FANCD2 and FANCI, the authors
proposed that the ID2 heterodimer could have two sets of pseudo-symmetrical
dsDNA/ssDNA binding sites, structures that could arise upon stalling of one or two
replication forks at an ICL.35 Notably, the Patel group discovered that, in addition to
binding to dsDNA and ssDNA, FANCD2 exhibits 3‟ to 5‟ exonucleolytic activity
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towards ssDNA in the presence of Mg2+ or Mn2+.164 However, the functional
significance for this activity remains to be established.
In addition, recent studies have established that FANCD2 monoubiquitination
is strongly stimulated through DNA binding. For example, the Kurumizaka and Sung
laboratories demonstrated that several forms of DNA, including dsDNA, ssDNA, and
Holliday junctions, could robustly stimulate the in vitro monoubiquitination of
FANCD2.45,

56

Of

note,

this

DNA-dependent

stimulation

of

FANCD2

monoubiquitination required both the presence of FANCI and its ability to bind to
DNA.56 Using Xenopus egg extracts, Sobeck and colleagues also demonstrated that the
monoubiquitination of FANCD2 could be stimulated with linear and branched dsDNA
structures but not with ssDNA or Y-shaped DNA.165 Expanding on these studies, the
Sobeck group recently demonstrated that while FANCD2 monoubiquitination is
strongly stimulated by circular and linear dsDNA, the monoubiquitination of FANCI
is strongly stimulated by ssDNA and only weakly induced by circular and linear
dsDNA, indicating a dichotomy in substrate specificity for both proteins.74 In addition,
through a time course study, the same group determined that the monoubiquitination
of FANCD2 in the presence of circular dsDNA and ssDNA occurs significantly earlier
than the monoubiquitination of FANCI.74 FANCD2 was also found to localize to
chromatin earlier than, and independent of, FANCI. In contrast, the localization of
FANCI to chromatin is FANCD2-dependent.74
Finally, recent studies from the D‟Andrea laboratory have established that
FANCD2 promotes RAS oncogene-induced senescence in part by promoting the
transcriptional activation of the TAp63 tumor suppressor gene.166 Monoubiquitinated

40

FANCD2 and FANCP/SLX4 bind to the TAp63 promoter and cooperate in the
transcriptional activation of TAp63.166 Genome-wide ChIP sequencing (ChIP-seq)
analysis revealed that following exposure to DNA damaging agents, FANCD2-Ub
binds to cis-regulatory sequences of numerous genes essential for epithelial
development and morphogenesis.166 This newly discovered function for FANCD2 in
transcriptional regulation is supported by other studies describing the binding of
FANCD2 to the TNF gene as well as the antioxidant genes GPX1 and TXNRD1, and
constitutes a novel dimension to the portfolio of FANCD2 functions.167, 168

Conclusions
The FANCD2 and FANCI proteins function at a pivotal point in the FA-BRCA
pathway and play an essential role in maintaining chromosome stability. Both proteins
are critical for hematopoietic stem cell homeostasis and the prevention of cellular
transformation. These key functions are achieved through what could be considered
disparate means: the promotion of error-free HR repair through the recruitment of
structure-specific endonucleases, replisome surveillance and resolution, nucleosome
remodeling, as well as transcriptional regulation. However, these functions are not
necessarily mutually exclusive and it is conceivable that FANCD2 and FANCI
facilitate these processes through the recruitment of multiple binding partners and/or
via a fundamental chromatin remodeling capacity. Many outstanding questions remain
to be addressed, including 1) the identification and characterization of structural and
functional domains of FANCD2 and FANCI, 2) cataloging the full spectrum and
functional significance of additional FANCD2 and FANCI posttranslational
41

modifications, 3) identification of the FANCI catalytic ubiquitin ligase machinery, 4)
determination of the function of monoubiquitinated FANCI (and FANCD2), and 5)
elucidation of the roles of FANCB and FAAP100 in the regulation of FANCL activity.
Much work remains to be done to clearly elucidate the structural and regulatory
mechanisms of these functions. The achievement of these goals will no doubt greatly
inform our understanding of the molecular etiology of FA and offer much needed
direction in the urgent quest for potential therapeutics.
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Abstract
Fanconi anemia (FA) is a rare recessive disease, characterized by congenital defects,
bone marrow failure, and increased cancer susceptibility. FA is caused by biallelic
mutation of any one of sixteen genes. The protein products of these genes function
cooperatively in the FA-BRCA pathway to repair DNA interstrand crosslinks (ICLs).
A central step in the activation of this pathway is the monoubiquitination of the
FANCD2 and FANCI proteins. Monoubiquitinated FANCD2 and FANCI localize to
discrete chromatin regions where they function in ICL repair. Despite their critical role
in ICL repair, very little is known about the structure, function, and regulation of the
FANCD2 and FANCI proteins, or how they are targeted to the nucleus and chromatin.
In this study, we describe the functional characterization of an amino-terminal
FANCD2 nuclear localization signal (NLS). We demonstrate that the amino terminal
58 amino acids of FANCD2 can promote the nuclear expression of GFP and is
necessary for the nuclear localization of FANCD2. Importantly, mutation of this
FANCD2 NLS reveals that intact FANCD2 is required for the nuclear localization of a
subset of FANCI. In addition, the NLS is necessary for the efficient
monoubiquitination of FANCD2 and FANCI and, consequently, for their localization
to chromatin. As a result, FANCD2 NLS mutants fail to rescue the ICL sensitivity of
FA-D2 patient cells. Our studies yield important insight into the domain structure of
the poorly characterized FANCD2 protein, and reveal a previously unknown
mechanism for the coordinate nuclear import of a subset of FANCD2 and FANCI, a
key early step in the cellular ICL response.
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Introduction
Fanconi anemia (FA) is a rare autosomal and X-linked recessive disease, characterized
by congenital abnormalities, pediatric bone marrow failure, and heightened cancer
susceptibility [1].

FA is caused by biallelic mutations in any one of 16 genes

(FANCA, -B, -C, -D1/BRCA2, -D2, -E, -F, -G, -I, -J/BRIP1, -L, -M, -N/PALB2, P/SLX4, O/RAD51C, Q/ERCC4) [2-4]. The protein products of these genes function
cooperatively in the FA-BRCA pathway to repair DNA interstrand crosslinks (ICLs)
and to maintain chromosome stability. A central step in the activation of the FABRCA pathway is the monoubiquitination of the FANCD2 and FANCI proteins.
Monoubiquitination of FANCD2 and FANCI is catalyzed by the FA core complex,
which is comprised of FANCA, FANCB, FANCC, FANCE, FANCF, FANCG,
FANCL, and FANCM, in addition to the E2 ubiquitin conjugating enzyme UBE2T, as
well as FAAP100, FAAP24, and FAAP20 [4,5]. Following monoubiquitination,
FANCD2 and FANCI co-localize in discrete nuclear foci with several well
characterized DNA repair proteins including BRCA1 and NBS1 [6-9]. However,
importantly, the domain structure, regulation, and function of both FANCD2 and
FANCI are poorly described. Furthermore, the mechanism(s) by which FANCD2 and
FANCI are localized to the nucleus remains unknown.
Several studies have established that the FANCD2 and FANCI proteins
function proximal to or within chromatin [6,8-10]. As FANCD2 and FANCI are
relatively large proteins, with molecular weights of 164 and 149 kDa, respectively, the
nuclear import of these proteins necessitates an energy-dependent active transport
mechanism. The most common nuclear protein transport mechanism involves the
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recognition of nuclear localization signals (NLSs) by members of the importin (Imp)
superfamily of nuclear transporters, followed by translocation through the nuclear pore
complexes [11]. NLSs generally comprise short stretches of basic amino acids either
alone (monopartite) or separated by one (bipartite) or two (tripartite) mutation-tolerant
linker regions of 10-12 amino acids (bipartite). NLSs in the cargo protein are
recognized by the Imp α subunit of the Imp α/β heterodimer or by Imp β alone, and
nuclear transport is coupled to GTP hydrolysis [11].
In this study, we describe the identification and functional characterization of a
NLS in the amino terminus of FANCD2. We demonstrate that the amino terminal 58
amino acids of FANCD2 can promote the nuclear expression of green fluorescent
protein (GFP). In addition, using deletion and site-directed mutagenesis strategies we
establish that the amino terminal 58 amino acids of FANCD2 are necessary for the
nuclear and chromatin localization of FANCD2 in FA-D2 patient-derived cells.
Importantly, we also demonstrate that the nuclear and chromatin localization of a
subset of the cellular pool of FANCI is dependent on the nuclear import of FANCD2.
Moreover, the FANCD2 NLS is required for the efficient DNA damage-inducible
monoubiquitination of FANCD2 and FANCI. Consequently, the FANCD2 NLS
mutants fail to rescue the ICL hypersensitivity of FA-D2 patient-derived cells. Our
results suggest that a subset of FANCI is translocated to the nucleus in a piggyback
mechanism with FANCD2, dependent on its amino-terminal NLS, and suggest that
FANCD2 and FANCI are targeted to the nucleus as a heterodimer. These findings
lend important insight into the structure and regulation of two poorly characterized
tumor suppressor proteins with key early roles in the cellular ICL response.
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Results
FANCD2 contains a highly conserved amino-terminal nuclear localization signal,
which facilitates nuclear expression of GFP
In silico analysis using cNLS mapper uncovered several high-scoring Imp α/dependent bipartite NLSs within the amino-terminal 58 amino acids of FANCD2
(Figs. S1A and B) [12]. In contrast, cNLS mapper did not predict any high scoring
NLSs in FANCI. A sequence alignment of FANCD2 from multiple species illustrates
strong evolutionary conservation in general (Fig. S1C). However, in contrast to the
sequence divergent carboxy-terminus, the alignment illustrates strong conservation of
several blocks of basic amino acids within the amino terminal 58 amino acids (Figs.
1A and S1C). To determine if this entire region or amino acids 1-27 or 24-58 harboring the two highest scoring predicted NLSs - were sufficient for nuclear
localization, we fused amino acids 1-58 (D2-1-58-GFP), 1-27 (D2-1-27-GFP), or 2458 (D2-24-58-GFP) of FANCD2 to the amino terminus of GFP (Fig. 1B). HeLa cells
were transiently transfected with wild type GFP (GFP-WT) and the FANCD2-GFP
fusion constructs and cells were analyzed by inverted fluorescence microscopy. HeLa
cells transiently expressing GFP-WT, D2-1-27-GFP, or D2-24-58-GFP all exhibited
uniform cytoplasmic and nuclear fluorescence (Fig. 1B). Conversely, cells transiently
expressing D2-1-58-GFP primarily exhibited nuclear fluorescence (Fig. 1B). Similar
findings were observed with IMR90 cells (Fig. S1D). These results demonstrate that
the amino terminal 58 amino acids of FANCD2 are necessary to promote exclusive
nuclear GFP localization. In support of an importin /-dependent mechanism of
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Figure 1. The amino terminal 58 amino acids of FANCD2 contain a highly
conserved nuclear localization signal, which facilitates nuclear expression of
GFP. (A) A Clustal Omega multiple sequence alignment of the amino terminus of
FANCD2 demonstrates strong evolutionary conservation of several blocks of basic
amino acids of this region, indicated by blue bars. The red box indicates the highly
conserved K4, R5, and R6 residues selected for mutagenesis. (B) The amino terminal
58 amino acids of FANCD2 are required to promote exclusive nuclear expression of
GFP. HeLa cells were transiently transfected with wild type GFP (GFP-WT), amino
acids 1-27 (D2-1-27-GFP), 24-58 (D2-24-58-GFP), or 1-58 (D2-1-58-GFP) of
FANCD2 fused to GFP followed by analysis by inverted fluorescence microscopy.
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nuclear import, treatment with ivermectin, a broad-spectrum inhibitor of importin /dependent nuclear import [13], inhibited the exclusive nuclear localization of D2-158-GFP, herein referred to as D2-NLS-GFP (Figs. S1E and F). In addition, mass
spectrometry analysis of FANCD2 immune complexes revealed the presence of
importin 1, as well as the nuclear pore complex proteins NUP160 and NUP155
(Supplemental Table 1). Using a chromatin fractionation approach we also observed
that the majority of GFP-WT resided in a soluble cytoplasmic and nuclear fraction (S)
(Fig. S1G, lane 5). While a large proportion of D2-NLS-GFP also resided in a soluble
cytoplasmic and nuclear fraction, a higher relative proportion of D2-NLS-GFP was
detected in a chromatin-associated nuclear fraction (C) (Figs. S1G, lane 9 and H).
Taken together these results demonstrate that the amino-terminal 58 amino acids of
FANCD2 harbors a bona fide NLS that can promote exclusive nuclear GFP
localization.

The FANCD2 NLS is required for the nuclear localization of FANCD2
To determine the functional significance of the FANCD2 NLS, we next generated
deletion and missense mutations of this amino acid sequence. Two amino-terminal
deletion mutations, FANCD2-N57, lacking amino acids 2-58, and FANCD2-N100,
lacking amino acids 2-101, were generated (Fig. 2A). In addition, using a site-directed
mutagenesis approach, amino acids K4, R5, and R6, the most highly conserved basic
amino acids within this region (Fig. 1A), were mutated to N4, N5, and N6, herein
referred to as FANCD2-3N (Fig. 2A). These FANCD2 cDNAs were cloned into the
pLenti6.2 lentiviral vector, which contains a carboxy-terminal V5 tag, and lentivirus
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Figure 2. The FANCD2 NLS is required for the nuclear localization of FANCD2.
(A) Schematic diagram of the FANCD2 constructs generated in this study. In addition
to the NLS, FANCD2 harbors a CUE (for coupling of ubiquitin conjugation to
endoplasmic reticulum degradation) ubiquitin-binding domain [47], a PCNAinteraction motif or PIP-box [19], and a carboxy-terminus EDGE motif [10]. (B) FAD2 cells stably expressing FANCD2-WT and FANCD2-∆N57 were incubated in the
absence (NT) or presence of 40 nM MMC for 24 h. Cells were then incubated in the
absence (-Pre-Perm) or presence (+Pre-Perm) of pre-permeablization buffer, fixed,
stained with mouse monoclonal anti-V5 antibody (green) and counterstained with
DAPI (blue). (C) FA-D2 cells stably expressing LacZ, FANCD2-WT, FANCD2∆N57, FANCD2-∆N100, and FANCD2-3N were incubated in the absence (NT) or
presence of MMC for 24 h, fixed, and stained with rabbit polyclonal anti-FANCD2
antibody, and counterstained with phalloidin and DAPI. At least 300 cells were scored
for cytoplasmic (Cyto.), nuclear (Nucl.), and both cytoplasmic and nuclear (Both)
localization

of
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FANCD2.
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was used to generate a series of PD20 FA-D2 patient-derived cells stably expressing
wild type or mutant FANCD2. These FA-D2 cells harbor a maternally inherited A-G
change at nucleotide 376 that leads to the production of a severely truncated protein,
and a paternally inherited missense hypomorphic mutation leading to a R1236H
change [14]. Immunofluorescence microscopy (IF) revealed that deletion of the
FANCD2 NLS resulted in exclusive cytoplasmic localization of FANCD2, in contrast
to wild type FANCD2, which exhibited both diffuse and focal nuclear localization
(Figs. 2B and C). Furthermore, permeabilization of FA-D2 cells expressing the
FANCD2-N57 mutant with non-ionic detergent resulted in complete loss of
fluorescent signal indicating the high solubility of cytoplasmic FANCD2-N57 (Fig.
2B). In contrast, nuclear and focal localization of wild type FANCD2 was largely
resistant to permeabilization (Fig. 2B). Similar findings were obtained with FA-D2
cells expressing FANCD2-N100 (Fig. 2C). In addition, a partial yet significant
defect in nuclear localization was observed for the FANCD2-3N mutant, compared to
wild type FANCD2 (Fig. 2C).

The FANCD2 NLS is required for the nuclear localization of a subset of FANCI
Next, we examined the sub-cellular localization of FANCI in our FA-D2 cell series. It
is important to note that the FA-D2 cells used in this study, like all known FA-D2
patient-derived lines, harbor hypomorphic FANCD2 mutations and express residual
FANCD2 protein [15]. IF analysis revealed that FANCI was uniformly present in both
the cytoplasm and nucleus of FA-D2 cells in the absence or presence of MMC (Figs.
3A and B). Importantly, complementation of FA-D2 cells with wild type FANCD2
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Figure 3. The FANCD2 NLS is required for the nuclear localization of a subset of
FANCI. (A) FA-D2 patient cells or FA-D2 cells stably expressing FANCD2-WT
were incubated in the absence (NT) or presence of MMC for 24 h, fixed, stained with
rabbit polyclonal anti-FANCD2 or anti-FANCI antibody and counterstained with
phalloidin and DAPI. AF-488, Alexa Fluor 488. (B) FA-D2 cells stably expressing
LacZ, FANCD2-WT, FANCD2-∆N57, FANCD2-∆N100, and FANCD2-3N were
incubated in the absence (NT) or presence of MMC for 24 h, fixed, and stained with
rabbit polyclonal anti-FANCI antibody, and counterstained with phalloidin and DAPI.
At least 300 cells were scored for cytoplasmic (Cyto.), nuclear (Nucl.), and both
cytoplasmic and nuclear (Both) localization of FANCI. (C) COS-7 cells were
transiently transfected with no DNA, FANCI-GFP, FANCI-GFP plus FANCD2-V5WT,

or

FANCI-GFP

plus

FANCD2-V5-∆N57.

Whole-cell

lysates

were

immunoprecipitated with anti-V5 or anti-GFP antibodies and immune complexes
immunoblotted

with

anti-GFP
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and

anti-V5

antibodies.
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(FANCD2-WT) led to a large increase in exclusive nuclear localization of FANCI
(Figs. 3A and B). Furthermore, MMC-inducible FANCI nuclear foci formation was
restored in these cells, consistent with previous studies [8,9] (Fig. 3A). Similar results
were obtained with hTERT-immortalized mutant and FANCD2-complemented KEAE
FA-D2 patient-derived cells [15] (Fig. S2A). In contrast to wild type FANCD2, both
the FANCD2-N57 and -N100 NLS mutants failed to promote the exclusive nuclear
localization of FANCI (Figs. 3B and S2B). Furthermore, a partial defect in FANCI
nuclear localization was observed for FA-D2 cells expressing FANCD2-3N (Fig. 3B).
To rule out the possibility that deletion of the amino-terminus of FANCD2 prevented
its heterodimerization with FANCI, we tested the ability of the FANCD2-N57
mutant to physically interact with FANCI by transiently transfecting COS-7 cells with
GFP-tagged FANCI and V5-tagged FANCD2-WT or FANCD2-N57 and examining
their ability to interact by co-immunoprecipitation. Co-expression of both FANCD2WT and FANCD2-N57 with FANCI led to its stabilization (Fig. 3C, upper panel,
lanes 3 and 4). Furthermore, the FANCD2-N57 mutant was capable of interacting
with FANCI and, when corrected for levels of protein input, no appreciable difference
in the level of interaction between FANCI and FANCD2-N57 and FANCI and
FANCD2-WT was observed (Fig. 3C, lower panels, lanes 3 and 4). Together, these
results establish that the nuclear localization of a subset of FANCI is dependent in part
on FANCD2, and suggest a piggyback mechanism of nuclear FANCI targeting that is
dependent on the FANCD2 amino-terminal NLS.
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The

FANCD2

NLS

is

required

for

efficient

FANCD2

and

FANCI

monoubiquitination and chromatin association
Next, we examined the consequences of disruption of the FANCD2 NLS on the
monoubiquitination and chromatin localization of FANCD2 and FANCI. Similar to
the FANCD2-K561R mutant that cannot be monoubiquitinated [6], mutation of the
FANCD2 NLS had a significant impact on its monoubiquitination: the N57 and
N100 NLS deletion mutants failed to undergo spontaneous or MMC-inducible
FANCD2 monoubiquitination (Fig. 4A, lanes 7-10). A faint band of similar molecular
weight to wild type FANCD2 can be seen in the -FANCD2 panel for FA-D2 cells
expressing FANCD2-N57 and -N100 (Fig. 4A, lanes 7-10). This is most likely the
hypomorphic FANCD2-R1236H missense mutant (see Materials and Methods) [14],
as this band is also present in FA-D2 cells expressing LacZ (lanes 1 and 2) and is not
recognized by the anti-V5 antibody (Fig. 4, lanes 7-10). The FANCD2-3N mutant
also

exhibited

considerably

reduced

spontaneous

and

MMC-inducible

monoubiquitination (Fig. 4A, lanes 11 and 12). Previous studies have demonstrated
that FANCD2 and FANCI monoubiquitination are interdependent [8,9]. Accordingly,
FANCI monoubiquitination was largely abrogated in FA-D2 cells stably expressing
the N57 and N100 NLS deletion mutants, similar to that observed in cells
expressing FANCD2-K561R (Fig. 4A, lanes 5-10). A very modest statistically
insignificant decrease in FANCI monoubiquitination was also observed for FA-D2
cells expressing the FANCD2-3N mutant (Fig. 4A, lanes 11 and 12). In addition, a
chromatin fractionation approach revealed that the FANCD2-N57, -N100, and -3N
mutants were largely defective in chromatin localization compared to FANCD2-WT
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Figure 4. The FANCD2 NLS is required for efficient FANCD2 and FANCI
monoubiquitination and chromatin association. (A) FA-D2 cells stably expressing
LacZ, FANCD2-WT, FANCD2-K561R, FANCD2-∆N57, FANCD2-∆N100 and
FANCD2-3N were incubated in the absence and presence of 250 nM MMC for 18 h,
and whole-cell lysates were immunoblotted with antibodies to FANCD2, V5, FANCI
and α-tubulin. The FANCD2 and FANCI L/S ratios are the ratios of
monoubiquitinated to nonubiquitinated protein, and were calculated by measuring
protein band intensities using ImageJ image processing and analysis software
(http://rsb.info.nih.gov/ij/). (B and C) FA-D2 cells stably expressing FANCD2-WT,
FANCD2-∆N57, FANCD2-∆N100 and FANCD2-3N were treated as above and cell
pellets were fractionated into soluble (S) and chromatin-associated (C) fractions.
Fractions were immunoblotted with antibodies against V5, FANCI, α-tubulin and
H2A. W, unfractionated whole cell extract.
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(Figs. 4B and C). Furthermore, while robust FANCI chromatin localization was
observed for cells expressing FANCD2-WT, in comparison, FANCI chromatin
localization was considerably diminished in cells expressing the FANCD2-N57, N100, and -3N mutants (Figs. 4B and C and S3). It is important to note that this
particular fractionation protocol does not distinguish between true chromatin and the
nuclear matrix.

The FANCD2 NLS mutants fail to correct the ICL sensitivity of FA-D2 patient
cells
FA patient-derived cells are hypersensitive to ICL-induced cytotoxicity and
clastogenicity [16]. Therefore, we next assessed the ability of the FANCD2 NLS
mutants to rescue the MMC sensitivity of FA-D2 cells. In a MMC clastogenicity
assay, FA-D2 cells expressing the N57 and N100 NLS mutants exhibited markedly
elevated levels of chromosome aberrations, including gaps and breaks, dicentrics, and
radial formations, compared with FA-D2 cells complemented with wild type FANCD2
(p = 0.001 and 1.1 x 10-5, respectively for 16 nM MMC) (Fig. 5A). In addition, in a
MMC cytotoxicity assay, similar to FA-D2 cells expressing FANCD2-K561R [6],
cells expressing the FANCD2-N57 and -N100 NLS mutants displayed increased
MMC sensitivity compared with cells expressing wild type FANCD2 (p < 0.05 at 50
nM for FANCD2-N57, -N100, and -K561R compared with wild type FANCD2)
(Fig. S4). Recent studies have demonstrated increased error-prone nonhomologous
DNA end joining (NHEJ) in FA patient cells [17]. Therefore, we also examined the
recruitment of DNA-PKCS to nuclear foci in FA-D2 cells expressing LacZ, wild type
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Figure 5. The FANCD2 NLS mutants fail to correct the ICL sensitivity of FA-D2
patient cells. (A) FA-D2 cells stably expressing LacZ, FANCD2-WT, FANCD2∆N57, FANCD2-∆N100, FANCD2-3N, or FANCD2-K561R were incubated in the
absence or presence of 8 or 16 nM MMC for 24 h and the numbers of chromosome
aberrations including gaps and breaks, dicentrics, and complex chromosome
aberrations, including radial formations, were scored. Metaphase spreads were
analyzed using a Zeiss AxioImager.A1 upright epifluorescent microscope with
AxioVision LE 4.6 image acquisition software. At least 80 metaphases were scored
per treatment. Error bars represent the standard error of the means. (B) FA-D2 cells
stably expressing LacZ, FANCD2-WT and FANCD2-∆N57 were incubated in the
absence (NT) or presence of 40 nM MMC for 18 h, and allowed to recover for 0, 4.5
or 7 h. Cells were then fixed, stained with rabbit polyclonal anti-DNA-PKCS pS2056,
and counterstained with DAPI. At least 300 cells were scored for nuclei with > 5
DNA-PKCS foci. Error bars represent the standard error of the means from two
independent

experiments.

***,
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p

<

0.001.
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FANCD2 or the FANCD2 N57 mutant, using an antibody raised against DNA-PKCS
phosphorylated on S2056, a marker of NHEJ [17,18]. Persistent increased DNA-PKCS
pS2056 nuclear foci formation was observed in FA-D2 cells expressing LacZ
following treatment with MMC, and this phenotype was rescued by wild type
FANCD2 (Fig. 5B). In contrast, we observed markedly increased MMC-inducible
DNA-PKCS pS2056 nuclear foci formation in FA-D2 cells expressing FANCD2 N57,
compared to cells expressing LacZ or wild type FANCD2 (Fig. 5B). Taken together,
these results demonstrate that the FANCD2 NLS is essential for the correct function of
the FA-BRCA pathway in the cellular ICL response.

Discussion
Despite their critical role in the cellular ICL response and their tumor suppressor
function, very little is known about the structure, function, and regulation of the
FANCD2 and FANCI proteins. For FANCD2, a large 1451 amino acid protein, only
two functional motifs, a PCNA-interaction motif, or PIP box, and a carboxy-terminus
EDGE motif, have been described to date [10,19]. Our laboratory has also recently
identified and characterized a CUE ubiquitin-binding domain in the amino-terminus of
FANCD2, which mediates noncovalent binding to ubiquitin, and is essential for
efficient cellular ICL repair [20]. In this study we describe the functional
characterization of an amino terminal FANCD2 NLS. While a previous study reported
the existence of a FANCD2 NLS, this study failed to examine the functional
consequences of its disruption in a FA-D2 patient-derived cell system [21]. Here, we
demonstrate that fusion of amino acids 1-58 of FANCD2 to the amino terminus of
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GFP drives its exclusive nuclear localization. cNLS mapper identified several high
scoring putative bipartite NLSs within this region, in particular, amino acids 2-27 and
24-55. However, in contrast to amino acids 1-58, fusion of either sequence to GFP
failed to drive exclusive nuclear GFP expression. Furthermore, mutation of K4, R5,
and R6, the most highly conserved block of basic amino acids within this region,
reduced, but did not abrogate, nuclear FANCD2 localization in FA-D2 cells. These
results establish that the functional NLS elements are harbored within the amino
terminal 58 amino acids. While the classical bipartite NLS comprises two clusters of
basic amino acids separated by a 10-12 amino acid linker region, exemplified by the
NLS of nucleoplasmin [22,23], unconventional bipartite NLSs with extended linker
lengths have also been described [24-26]. However, cNLS mapper searches for both
conventional and unconventional bipartite NLSs and only detected the former [12]. In
addition to monopartite and bipartite NLSs, at least two other classes of NLS have
been described: tripartite containing three clusters of basic amino acids similar to
those found in L-periaxin and the epidermal growth factor receptor (EGFR) family
[27,28], as well as NLSs containing dispersed basic residues within a random coil
structure such as that found for 5-lipoxygenase [29]. These NLSs are poorly
characterized in comparison with their mono- and bi-partite counterparts and are not
predicted by cNLS mapper or PSORT II amino acid prediction algorithms. While the
crystal structure of the murine Fanci-Fancd2 heterodimer (ID2) has been solved, the
majority of the NLS described in this study was not crystallized precluding
speculation about the structure of this region [30]. It is also important to note that
FANCD2 harbors several putative phosphorylation sites within the amino terminal 58
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amino acids (PhosphoSitePlus), which may also contribute to the regulation of its
nuclear localization [31].
Our studies suggest that FANCD2 is imported to the nucleus via an importin
/-dependent mechanism as treatment with ivermectin, a broad-spectrum inhibitor of
importin /-dependent nuclear import [13], results in markedly decreased exclusive
nuclear localization of D2-NLS-GFP. Furthermore, using mass spectrometry we have
recently detected importin 1, as well as the nuclear pore complex proteins NUP160
and NUP155, in FANCD2 immune complexes (Supplemental Table 1). In summary,
our functional analyses have revealed the following important points: 1) the NLS is
necessary for the nuclear localization of FANCD2, 2) the FANCD2 NLS is required
for the nuclear localization of a subset of FANCI, 3) the NLS is necessary for the
efficient monoubiquitination of both FANCD2 and FANCI, and 4) the NLS is
required for the localization of both FANCD2 and FANCI in chromatin.
Consequently, FA-D2 cells expressing FANCD2 NLS deletion mutants are defective
in the repair of ICLs. Our studies provide additional important insight into the domain
structure of FANCD2, and suggest a novel FANCD2-dependent piggyback
mechanism of FANCI nuclear import. Furthermore, our results suggest that FANCD2
and FANCI are targeted to the nucleus as a heterodimer. These findings lend
important insight into the structure and regulation of two poorly characterized tumor
suppressor proteins with key early roles in the cellular ICL response.
Here we have established that FANCI is, at least partially, dependent on
FANCD2 for both its nuclear localization and chromatin association: In FA-D2 patient
cells, as well as FA-D2 cells expressing the FANCD2 NLS mutants, FANCI localized
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diffusely to the cytoplasm and nucleus. The introduction of wild type FANCD2 into
these cells resulted in a large increase in exclusively nuclear FANCI as well as its
chromatin localization, particularly following exposure to MMC. In contrast, we, and
others, have observed robust nuclear localization of FANCD2 in FA-I cells, indicating
that FANCD2 is not dependent on FANCI for its nuclear localization [32]. A previous
study of the patient-derived FANCI R1299X nonsense mutant, which lacks its
carboxy-terminal 30 amino acids, demonstrated that FANCI harbors a monopartite
NLS in this region [32]. While loss of this NLS reduced FANCI nuclear accumulation,
this NLS was not completely necessary for FANCI or FANCD2 nuclear accumulation,
strongly suggesting the existence of alternative nuclear import mechanisms for both
proteins, consistent with our data [32]. The elucidation of the crystal structure of the
ID2 heterodimer indicates that the FANCD2 and FANCI NLSs are spatially separated
within this structure [30], arguing against the simultaneous contribution of both NLSs
to nuclear import of the ID2 complex. Taken together, these results suggest that
FANCI localizes to the nucleus via FANCD2-independent and -dependent
mechanisms (Fig. 6). These findings are also consistent with the observation that only
a minor fraction of the cellular pools of FANCD2 and FANCI physically interact
[8,9], reinforcing the concept of ID2 complex-independent functions for both proteins,
such as that recently described by Chaudhury and colleagues [33]. A recent study has
also established that a fraction of FANCD2 is transported to the nucleus following
MMC exposure via an indirect interaction with importin 4 (IPO4), which is mediated
by the C/EBP transcription factor [34]. While clearly important for ICL repair, this
mechanism in unlikely to be the major mechanism of FANCD2 nuclear import as
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robust levels of nuclear FANCD2 were observed in C/EBP-null mouse embryonic
fibroblasts as well as cells depleted of IPO4 and C/EBP [34]. Nevertheless, this
C/EBP/IPO4-dependent FANCD2 nuclear import mechanism could account for the
low levels of nuclear FANCD2-N57 and FANCD2-N57 observed in our studies.
Interestingly, we observed markedly increased MMC-inducible chromosome
aberrations and DNA-PKCS pS2056 nuclear foci formation in FA-D2 cells expressing
FANCD2-N57, compared to FA-D2 cells expressing LacZ. These results suggest
that the FANCD2-N57 mutant may act in a dominant-negative manner. The FA-D2
patient-derived cells used in this study are compound heterozygous for FANCD2
mutations (see Materials and Methods). This variant is detectable by immunoblotting
(see Fig. 4A, top panel) and is predicted to retain residual or partial function. Indeed,
the vast majority of FA-D2 patient-derived cells retain residual FANCD2 function
with complete loss of FANCD2 predicted to result in embryonic lethality [15]. Our
results suggest that the FANCD2-N57 mutant interferes with residual FANCD2
R1236H function, perhaps competing with FANCD2 R1236H for heterodimerization
with FANCI, or in a manner analogous to missense p53 mutations, by assembling into
nonfunctional homo-oligomers, the formation of which has been suggested by
previous studies [30,35].
Based on our findings, and those of several other groups, we propose the
following model for early steps in the FA-BRCA pathway of ICL repair (Fig. 6). A
subset of the total cellular pools of FANCD2 and FANCI associate in the cytoplasm to
assemble into the ID2 heterodimer. The ID2 heterodimer is transported to the nucleus
most likely via an importin /-mediated transport process, using the amino terminal
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Figure 6. FANCD2-dependent and -independent mechanisms of FANCI nuclear
localization. We propose that a subset of FANCI (blue) associates with FANCD2
(red) in the cytoplasm, and that the ID2 heterodimer is transported to the nucleus via
an importin α/β (brown)-mediated transport mechanism, using the amino terminal
FANCD2 NLS (light green). Nuclear ID2 binds to DNA (orange) and is also
phosphorylated by the ATM/ATR kinases (dark green). One or both of these events
may trigger ID2 complex restructuring, facilitating FANCD2 and FANCI
monoubiquitination by FANCL (black), UBE2T (yellow) and the FA core complex
(not shown).
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NLS of FANCD2. Once inside the nucleus the ID2 heterodimer is targeted to sites of
ICL damage possibly via the association of FANCD2 with PCNA and the replication
fork machinery [19]. Recent in vitro studies have demonstrated that FANCI binding to
DNA is necessary for robust stimulation of the monoubiquitination of FANCD2 [36].
However, analysis of the ID2 crystal structure indicates that the FANCD2 K561 side
chain, the site of monoubiquitination, is embedded within the ID2 interface [30].
Furthermore, a solvent accessible tunnel adjacent to FANCD2 K561 is predicted to be
too small to accommodate the active site of the UBE2T ubiquitin-conjugating enzyme
[30,37]. Therefore, either 1) monoubiquitination occurs on FANCD2 and FANCI
monomers prior to ID2 heterodimerization or 2) binding of the ID2 complex to DNA
leads to a conformational change in the ID2 structure leading to the exposure of
K561R and FANCI K523, and their subsequent monoubiquitination, as has been
proposed [36]. A recent study by Sareen and colleagues suggests that activation of the
FA-BRCA pathway coincides with dissociation of FANCD2 and FANCI [38]. ID2
dissociation is triggered by ATR/ATM-mediated phosphorylation of a cluster of at
least six FANCI SQ motifs, and is followed by the monoubiquitination of FANCD2
[38,39]. Once monoubiquitinated, FANCD2 can then facilitate the recruitment of
several structure specific nucleases, including FAN1 and FANCP/SLX4, initiating the
process of ICL removal [40-46].
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Materials and Methods
Cell culture
COS-7, HeLa, and IMR90 cells were grown in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 12% v/v FBS, L-glutamine and penicillin/streptomycin.
293FT viral producer cells (Invitrogen) were cultured in DMEM containing 12% v/v
FBS, 0.1 mM non-essential amino acids (NEAA), 1% v/v L-glutamine, 1 mM sodium
pyruvate and 1% v/v penicillin/streptomycin. PD20 FA-D2 (FANCD2hy/-) cells were
purchased from Coriell Cell Repositories (Catalog ID GM16633). These cells harbor a
maternally inherited A-G change at nucleotide 376 that leads to the production of a
severely truncated protein, and a paternally inherited missense hypomorphic (hy)
mutation leading to a R1236H change [14]. To generate stable lines expressing wild
type or mutant FANCD2, FA-D2 cells were infected with pLenti6.2-FANCD2
(Invitrogen) lentivirus, followed by selection in DMEM supplemented with 12% v/v
FBS, L-glutamine, penicillin/streptomycin and 2 μg/ml blasticidin. KEAE FA-D2
cells and KEAE FA-D2 + FANCD2 cells were a kind gift from Detlev Schindler of
the University of Würzburg [15]. These cells were telomerase immortalized using
pBABE-hTERT and grown in DMEM supplemented with 12% v/v FBS, L-glutamine,
penicillin/streptomycin and 0.75 μg/ml puromycin.

Antibodies and immunoblotting
For immunoblotting analysis, cell pellets were washed in PBS and lysed in 2% w/v
SDS, 50 mM Tris-HCl, 10 mM EDTA. Proteins were resolved on NuPage 3-8% w/v
Tris-Acetate or 4-12% w/v Bis-Tris gels (Invitrogen) and transferred to polyvinylidene
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difluoride (PVDF) membranes. The following antibodies were used: rabbit polyclonal
antisera against FANCD2 (NB100-182; Novus Biologicals), FANCI (Dr. Patrick
Sung, Yale University), H2A (07-146; Millipore), and mouse monoclonal sera against
α-tubulin (MS-581-PO; Neomarkers), GFP (sc-9996; Santa Cruz), and V5 (R96025;
Invitrogen).

Immunofluorescence microscopy
For immunofluorescence microscopy (IF) analysis, cells were seeded in 4-well tissue
culture slides (BD Falcon) and treated with mitomycin C (MMC) for 18 h. Soluble
cellular proteins were pre-permeabilized with 0.3% v/v Triton X-100 and cells were
fixed in 4% w/v paraformaldehyde and 2% w/v sucrose at 4°C followed by
permeabilization in 0.3% v/v Triton X-100 in PBS. Fixed cells were blocked for 30
minutes in antibody dilution buffer (5% v/v goat serum, 0.1% v/v NP-40, in PBS) and
incubated with primary antibody for 1 h. Cells were washed three times in PBS, as
well as permeabilization buffer, and incubated for 30 min at room temperature with an
Alexa Fluor 488-conjugated secondary antibody combined with Texas Red labeled
phalloidin. The slides were counterstained and mounted in vectashield plus 4‟6diamidine-2-phenylindole dihydrochloride (DAPI) (Vector Laboratories). Nuclear foci
were analyzed using a Zeiss AxioImager.A1 upright epifluorescent microscope with
AxioVision LE 4.6 image acquisition software. Primary antibodies used for IF were
anti-FANCD2 (NB100-182; Novus Biologicals), anti-FANCI (Dr. Patrick Sung, Yale
University), anti-DNA-PKCS pS2056 (ab18192; Abcam), and anti-V5 (R960-25;
Invitrogen).
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Plasmids, site-directed mutagenesis, and transient transfections
The full length, N57, and N100 FANCD2 cDNA sequences were TOPO cloned into
the pENTR⁄D-TOPO (Invitrogen) entry vector, and subsequently recombined into the
pLenti6.2/V5-DEST (Invitrogen) destination vector and used to generate lentivirus for
the generation of stable cell lines. The FANCD2-KRR4NNN (FANCD2-3N) cDNA
was generated by site-directed mutagenesis of the wild type FANCD2 cDNA using the
Quikchange Site-directed Mutagenesis Kit (Stratagene). The forward and reverse
oligonucleotide

sequences

used

are

as

follows:

TTCACCATGGTTTCCAACAACAACCTGTCAAAATCTGAGG-3‟;

FP,

5‟-

RP,

5‟-

CCTCAGATTTTGACAGGTTGTTGTTGGAAACCATGGTGAA -3‟. The FANCD2
GFP fusion vectors D2-1-27-GFP, D2-24-55-GFP, and D2-1-58-GFP were generated
by PCR amplifying the coding sequences of amino acids 1-27, 24-55, or 1-58 of
FANCD2 and directionally cloning these fragments into the multiple cloning site of
pEGFP-N1 (Clontech). The FANCI-GFP construct was a gift from Tony Huang in the
Department of Biochemistry at New York University School of Medicine. COS-7,
HeLa, and IMR90 cells were transiently transfected with plasmid DNA using Fugene
6 (Roche) at a 1:3 ratio (g DNA:L Fugene 6) in Opti-MEM. After incubating for 24
h, GFP fluorescence was monitored using a Zeiss AxioImager X-Cite series 120Q
inverted fluorescence microscope with AxioVision LE 4.8 image acquisition software.
Ivermectin (Sigma) was added to a final concentration of 25 M 4 h following
transfection.
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Cellular fractionation
Soluble proteins were removed by extraction in cytoskeletal buffer (CSK) (10 mM
PIPES pH 6.8, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 1 mM EGTA, and
0.5% v/v Triton-X-100) for 10 minutes at 4oC. Pellets were washed once with CSK
buffer, lysed in SDS sample buffer (2% w/v SDS, 50 mM Tris-HCl pH 7.4, 10 mM
EDTA), boiled for 15 min, followed by sonication for 10 s at 10% amplitude using a
Fisher Scientific Model 500 Ultrasonic Dismembrator.

Chromosome breakage analysis
Cells were incubated in the absence or presence of MMC for 18 h. Prior to harvesting,
cells were treated with 0.1 ug/ml Colcemid (Gibco/Invitrogen) for 2 h; pellets were
then incubated in 0.075 M KCl at 37°C for 18 min, followed by fixation in Carnoy‟s
fixative (3:1 methanol:glacial acetic acid). Cells were dropped onto chilled slides, airdried, and then stained with 2.5% w/v Giemsa solution (Sigma). Metaphases were
analyzed using a Zeiss AxioImager.A1 upright epifluorescent microscope with Axio
Vision LE 4.6 image acquisition software.
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Abstract
Fanconi anemia (FA) is a rare genetic disease characterized by bone marrow failure,
congenital defects, and increased cancer susceptibility. FA is caused by mutation in
any of 19 known genes. The protein products of these genes function collectively in
the FA-BRCA pathway to repair DNA interstrand-crosslinks (ICLs). Upon exposure
to ICL-inducing agents, the FA core complex catalyzes the monoubiquitination of the
FANCD2 and FANCI proteins, activating these proteins for ICL repair. FANCD2 is
also posttranslationally modified by phosphorylation following exposure to DNA
damaging agents and upon disruption of DNA replication. The DNA damageinducible posttranslational regulation of the FA pathway has been extensively studied,
however, few studies have explored the regulation of the FANCD2 and FANCI
proteins independent of DNA damage. In this study, we have determined that
FANCD2 is phosphorylated in a DNA damage-independent manner, which appears to
be mediated by CDK and is maximal during S phase, coinciding with FANCD2
monoubiquitination. We have also identified a putative CDK phosphorylation site
cluster proximal to K561. Phosphorylation at this cluster has a negative regulation of
FANCD2 monoubiquitination. We hypothesize that CDK-mediated FANCD2
phosphorylation is critical for the efficient regulation of FANCD2 function during S
phase.

Introduction
Fanconi anemia (FA) is a rare recessive disease, characterized by congenital
abnormalities, progressive pediatric bone marrow failure, and heightened cancer
108

susceptibility [1]. FA is caused by mutation in any one of 19 genes (FANCA, -B, -C, D1/BRCA2, -D2, -E, -F, -G, -I, -J/BRIP1, -L, -M, -N/PALB2, -P/SLX4, O/RAD51C,
Q/ERCC4, R/RAD51, S/BRCA1, T/UBE2T) [2-4]. The FA proteins function
cooperatively in the FA-BRCA pathway to repair DNA interstrand crosslinks (ICLs)
and to prevent chromosome instability. The core complex, comprised of
FANCA/B/C/E/F/G/L, along with the E2 conjugating enzyme FANCT, FANCM,
FAAP100/24/20, and MHF1/2 catalyze the monoubiquitination of the FANCD2 and
FANCI proteins [4,5]. This central activation step promotes FANCD2 and FANCI colocalization to discrete nuclear foci with several downstream DNA repair proteins,
including FANCS/BRCA1 and NBS1 [6-9]. Monoubiquitinated FANCD2 has been
shown to recruit the structure specific endonucleases FAN1 and FANCP/SLX4, which
suggests that this modified form of FANCD2 functions to promote one or more
incision steps during the ICL repair process [10,11]. FANCD2 and FANCI are also
posttranslationally modified by phosphorylation in response to DNA damage by ATM
(Ataxia-telangiectasia
phosphorylates

mutated)

FANCD2

in

and

ATR

response

to

(ATM

and

Rad3-related).

IR

exposure

ATM

independently

of

monoubiquitination [12]. Phosphorylation of FANCD2 by ATR promotes FANCD2
monoubiquitination in response to exposure to ICL-inducing agents and is important
in its function in ICL repair [13]. FANCI phosphorylation by ATM/ATR on six
SQ/TQ residues has been linked to activation of the FA-BRCA pathway, potentially
by promoting the dissociation of the FANCD2-FANCI heterodimer [14,15].
Although the main focus concerning FANCD2 has been based on DNA
damage activation, FANCD2 has also been shown to be monoubiquitinated during
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unperturbed cell cycle progression in S phase, where it co-localizes with BRCA1 and
RAD51 [16]. With the addition of hydroxyurea (HU), which arrests DNA replication,
FANCD2 has been shown to protect stalled replication forks from degradation by
MRE11, and to promote replication restart at stalled replication forks by recruiting and
interacting with CtIP (CtBP-interacting protein) [17,18]. These studies suggest that
FANCD2 has many roles outside of the more recognized DNA damage inducible
function, specifically during the cell cycle.
In this study, we have determined that FANCD2 is phosphorylated in a DNA
damage-independent manner, which we believe is essential for the regulation of
FANCD2 function during unperturbed S phase. Many DNA repair proteins are
regulated by cyclin-dependent kinase (CDK) mediated phosphorylation, such as
BRCA1 and NBS [19,20]. Here we show that FANCD2 is a substrate of CDK through
immunoprecipitation studies as well as CDK inhibitor experiments. Importantly, we
have discovered and are beginning to characterize a putative CDK site cluster in
FANCD2 that is positioned proximal to FANCD2s site of monoubiquitination.
Missense mutations of these sites yields unexpected results, a phospho-mimetic
mutant fails to induce a response to DNA replication or damaging agents and a
phospho-dead mutant is constitutively activated. The findings from this study establish
novel phosphorylation of FANCD2 in unperturbed S phase and reveal a CDK
phosphorylation site cluster that is posttranslationally modified to negatively regulate
FANCD2 monoubiquitination.
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Results
FANCD2 is phosphorylated in the absence of DNA damage
Initial findings from a previous study using FANCD2 patient cells expressing
FANCD2-WT, FANCD2-K561R, and truncation mutants, suggested that FANCD2
may be phosphorylated in the absence of DNA damage (data not shown). In order to
analyze the phosphorylation of FANCD2 under these conditions, a lambda
phosphatase assay was performed. Lambda phosphatase cleaves phosphorylated
serine, threonine, and tyrosine residues [21]. HeLa, U2OS, COS7, and BJ-TERT cells
were treated with and without MMC and lysates were incubated in the presence and
absence of lambda phosphatase (Fig. 1A). When comparing incubation with and
without lambda phosphatase, the electrophoretic mobility of FANCD2 increases in
both the presence and absence of MMC, indicating that FANCD2 is phosphorylated
independent of DNA damage. It is interesting to note that this is not seen with FANCI.
To ensure this finding is due to phosphorylation, a lambda phosphatase assay
was done using HeLa, FA-D2 patient-derived cells stably express the empty vector,
FANCD2-WT, and FANCD2-K561R, which were treated for the indicated times with
lambda phosphatase (Fig. 1B). Reaction products were then run on a Phos-tag gel;
Phos-tag is a novel phosphate-binding tag that binds phosphorylated proteins [22].
Treatment with lambda phosphatase causes the stabilization of non-phosphorylated
FANCD2 and limits the isoforms present when compared to lack of treatment. To
ensure the molecular weight difference in FANCD2 was due to the cleavage of
phosphate groups and not an unforeseen interaction with the lambda phosphatase
enzyme, protein phosphatase 1 (PP1) enzyme was used (Fig. 1C). This enzyme
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Figure 1. FANCD2 is phosphorylated in the absence of DNA damage. (A) HeLa,
U2OS, COS-7, and BJ-TERT cells were incubated in the absence (-) and presence (+)
of 250 nM MMC for 18 h and whole-cell lysates were subsequently treated with (+)
and without (-) lambda phosphatase for 2 h 30°C and immunoblotted with antibodies
against FANCD2, FANCI, and α-tubulin. (B) HeLa, FA-D2 cells with empty plasmid
or stably expressing FANCD2-WT, and FANCD2-K561R were incubated with
lambda phosphatase for 2, 4, 16 h at 30°C and run on a SuperSep Phos-tag gel. They
were immunoblotted against FANCD2 and V5. (C) HeLa and U2OS cells were
incubated with lambda phosphatase or PP1 for 2 h at 30°C and immunoblotted against
FANCD2. ∆, molecular weight shift difference between nonphosphorylated and
phosphorylated

FANCD2.
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cleaves phosphates from serine and threonine residues. Much like lambda
phosphatase, PP1 also caused FANCD2 to migrate faster in the gel in both HeLa and
U2OS cells, indicating a true phosphorylation pattern. Taken together, this data
indicates that FANCD2 is phosphorylated on several residues, in a DNA damageindependent manner.

FANCD2 phosphorylation is maximal in S phase
It is known that FANCD2 is activated through monoubiquitination during S phase of
the cell cycle; however, the regulation behind this cycle dependent posttranslational
modification is currently unknown [16]. To determine if FANCD2 is differentially
phosphorylated throughout the cell cycle, several cell synchronizations were
performed. Using HeLa cells, a nocodazole block was performed, blocking the cells in
early M phase (Fig. 2A). Cells were then released for the indicated times and cell
pellets were separated into three, treating with and without lambda phosphatase for 2
h, and the third was fixed and stained with propidium iodide for FACS analysis.
Although there is a molecular weight shift difference when looking at FANCD2 via
western blot, this shift in migration is most prominent at 12 and 15 h post-release,
correlating with S phase of the cell cycle. Again, when probing for FANCI, no
molecular weight shift was observed. Cyclin A was used as a cell cycle marker, as it is
active and upregulated in S and G2 phases of the cell cycle [23]. To explore FANCD2
phosphorylation during the cell cycle, a second synchronization method was
performed. Using both HeLa (Fig. 2B) and U2OS cells (Fig. S1), a double thymidine
block arrest was used to synchronize in G1/S phase of the cell cycle. A lambda
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Figure 2. FANCD2 phosphorylation is maximal in S phase. (A) HeLa cells were
synchronized by nocodazole block or double thymidine block (B). The cell cycle
phase was determined by flow cytometric analysis of DNA content and whole-cell
lysates were incubated in the absence (-) and presence (+) of lambda phosphatase for 2
h at 30°C and immunoblotted with antibodies against FANCD2, FANCI, and Cyclin
A. AS, asynchronous whole-cell lysate.
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phosphatase assay and FACs analysis was then performed, and in a similar manner as
the nocodazole block, a maximal molecular weight shift difference is seen 0-4 h postrelease. This is indicative of S phase of the cell cycle, suggesting there is a DNA
damage independent phosphorylation of FANCD2 that correlates with its
monoubiquitination.

Non-DNA damage inducible phosphorylation of FANCD2 is independent of
ATM, ATR, and the core complex member FANCA
It is known that FANCD2 and FANCI are phosphorylated by the DNA damage
response kinases ATM and ATR [12-14]. To test if ATM was the kinase responsible
for the phosphorylation of FANCD2 in S phase seen via the lambda phosphatase
assay, PEBS (ATM-/-) and YZ5 (ATM+/+) fibroblasts were used for a double
thymidine block and subsequent lambda phosphatase assay, as described previously
(Fig. 3A). If ATM is essential for this posttranslational modification, the molecular
weight difference in FANCD2 treated with and without lambda phosphatase would be
absent or reduced. In comparing PEBS and YZ5 cells, there is no difference in
FANCD2s electrophoretic mobility with the addition of the lambda phosphatase
enzyme, indicating this phosphorylation is largely independent of ATM. To determine
ATRs importance in FANCD2s phosphorylation in the absence of DNA damage and
in S phase of the cell cycle, 066 Seckel patient lymphoblasts (ATR-/-) and wild-type
lymphoblasts were then used (Fig. 3B). Similar to the results seen in ATM deficient
cells, ATR does not appear to be crucial for this mobility in FANCD2. The FA core
complex

is

responsible

for

orchestrating
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FANCD2s

monoubiquitination;

Figure 3. Non-DNA damage inducible phosphorylation of FANCD2 is
independent of ATM, ATR, and the core complex member FANCA. (A) PEBS
(ATM-/-) and YZ5 (ATM+/+) fibroblasts were synchronized by double thymidine and
released for 0 and 2 h followed by treatment with lambda phosphatase for 2 h at 30°C
and immunoblotted with antibodies to FANCD2, FANCI, ATM, and α-tubulin. (B)
066 (ATR-/-) and PD7L (WT) lymphoblasts were synchronized by double thymidine
block and released for 0 and 2 h followed by treatment with lambda phosphatase for 2
h at 30°C and immunoblotted with antibodies against FANCD2, FANCI, ATR,
CHK1, and pS345 CHK1. (C) 6914 (FA-A) and 6914 + FANCA were synchronized
by double thymidine block and released for 0 and 2 h followed by treatment with
lambda phosphatase for 2 h at 30°C and immunoblotted with antibodies against
FANCD2,

FANCI,

FANCA,
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and

α-tubulin.
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therefore, we next assessed the ability of FANCD2 to become phosphorylated in the
absence of FANCA. FA-A (6914) and FA-A corrected cells (6914 + FANCA) were
arrested in early S phase by double thymidine treatment, followed by incubation in the
presence and absence of lambda phosphatase (Fig. 3C). As seen in the ATR and ATM
deficient cells, in the absence of FANCA, there is still a phosphorylation shift
visualized. These results combined suggest that the DNA damage response kinases are
not responsible for FANCD2s phosphorylation in the cell cycle and this
phosphorylation event occurs either upstream or independently of FANCD2s
monoubiquitination. To corroborate FANCD2 phosphorylation acting upstream or
independently of FANCD2s monoubiquitination, FA-D2 + empty, FANCD2, and
K561R cell lines were used incubated with lambda phosphatase for 2, 4, and 16 h
(Fig. S2). FANCD2 K561R is unable to become monoubiquitinated; however, a
molecular weight shift difference is still seen. This indicates that monoubiquitination
is not essential for FANCD2s phosphorylation.

FANCD2 is a potential substrate of CDK phosphorylation
Cell cycle progression is regulated through phosphorylation by CDKs [24]. We next
assessed whether FANCD2 was a substrate of CDK phosphorylation by using
FA-D2 patient cells stably expressing LacZ-V5 or FANCD2-V5 and performing an
immunoprecipitation (IP) (Fig. 4A). V5 agarose was used to pull down FANCD2-V5.
A pan phospho serine antibody was then used, which recognizes phosphorylated
substrates of CDK, and FANCD2 is seen in the FA-D2 patient cell line expressing
FANCD2. A second IP was performed using a different cell system, U2OS cells stably
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Figure 4. FANCD2 is a potential substrate of CDK phosphorylation. (A) FA-D2
cells stably expressing LacZ-V5 and FANCD2-V5 were immunoprecipitated with
anti-V5 agarose and immune complexes were immunoblotted with anti-FANCD2 and
anti-pSCDK. (B) U2OS and U2OS cells stably expressing 3X FLAG FANCD2-WT
were immunoprecipitated with anti-FLAG agarose and immune complexes were
immunoblotted with anti-FANCD2, anti-FLAG, and anti-pSCDK. (C) U2OS 3X
FLAG FANCD2 immunoprecipiated as shown in (B), was used for phospho
enrichment and further mass spectrometry analysis revealed several phosphorylated
FANCD2

isoforms.
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expressing 3XFLAG tagged FANCD2 (Fig. 4B). Here we used FLAG agarose and
performed an IP with U2OS and U2OS 3X FLAG-FANCD2 fibroblasts. Similar
results were obtained as with FA-D2 FANCD2-V5; FANCD2 is a substrate of CDK as
seen through the pan phospho serine antibody. The U2OS 3XFLAG FANCD2 IP was
then run on a commassie gel in triplicate and the FANCD2 bands were combined and
a tryptic digestion was performed in preparation for mass spectrometry (Fig. S3).
Using TiO2 phosphopeptide enrichment, these samples were analyzed for phospho
peptides (Fig. 4C). Several known ATM/ATR sites were found in this sample, as well
as one serine protein site, S692, which resides in the phosphoCDK cluster proximal to
K561. The CDK consensus sequence is [S/T*]PX[K/R], however, known DNA repair
proteins, such as BRCA1, have been shown to be phosphorylated by CDK through
only containing S/P of the consensus sequence.

Treatment with CDK inhibitor purvalanol A alters FANCD2s phosphorylation
shift
As it was determined that FANCD2 is a potential substrate of CDK, we wanted to
establish which CDK was responsible. If maximal FANCD2 phosphorylation occurs
during S phase of the cell cycle, CDK2 could be the potential kinase responsible. In
order to determine a specific CDK was responsible for FANCD2s non-DNA damaging
phosphorylation, various CDK inhibitors with differing specificities were utilized
(Fig. 5A). HeLa cells were incubated with each indicated inhibitor for 24 h and a
lambda phosphatase assay was performed to determine if a specific CDK is required
for FANCD2s phosphorylation (Fig. 5B). Two chemicals that comprise CDK2
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Figure 5. Treatment with CDK inhibitor purvalanol A alters FANCD2s
phosphorylation shift. (A) Table depicting CDK inhibitors and their specific targets.
(B) HeLa cells were treated for 24 h with 10 μM Olomoucine, 10 μM Olomoucine II,
10 μM Purvalanol A, 10 μM RO-3306, and 20 μM Roscovatine and whole-cell lysates
were treated in the absence (-) and prescence (+) of lambda phosphatase for 2 h at
30°C and immunoblotted with antibodies against FANCD2. (B) HeLa cells were
treated with 10 uM Purvalanol A and 10 uM RO-3306 for 2, 4, 8, 24 h and incubated
with (+) and without (-) lambda phosphatase. Immunoblotting was performed and
antibodies

against

FANCD2

and
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α-tubulin

were

used.
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inhibition, Purvalanol A and Roscovitine, were shown to reduce FANCD2s mobility
with the addition of the lambda phosphatase enzyme, indicating CDK2 could be
needed. To further examine treatment with CDK inhibitors, HeLa cells were incubated
for 2, 4, 8, or 24 h with either the CDK2 inhibitor Purvalanol A or the CDK1 specific
inhibitor RO-3306 (Fig. 5C). A lambda phosphatase assay was then performed. As
expected from the previous result, RO-3306 does not have an effect on FANCD2s
phosphorylation. However, treatment with Purvalanol A, specifically for 4 and 8 h,
depletes the mobility shift of FANCD2 with the addition of the enzyme. These results
indicate CDK2 could be the potential kinase resulting in FANCD2s phosphorylation
during S phase of the cell cycle.

FANCD2 contains a conserved putative CDK consensus site cluster
As the previous results suggest that FANCD2 is a substrate of CDK, the FANCD2
sequence was analyzed for potential CDK phosphorylation sites. A multiple sequence
alignment of FANCD2 found strong evolutionary conservation in a cluster of three
S/P sites: S525, S624, S726 (Fig. 6A). Interestingly, when looking at the murine
crystallized structure of FANCD2, this putative CDK cluster is situated in close
proximity to FANCD2s monoubiquitination site (Fig. 6B). As previous results have
established a connection between maximal FANCD2 phosphorylation occurring
during S phase, which is when FANCD2 is monoubiquitinated during the cell cycle,
the position could shed light on FANCD2s activation. It is important to note that the
S/P site found through mass spec analysis, S692, is also situated within this cluster,
albeit on a short uncrystallized loop. To determine the functional significance of the
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Figure 6. FANCD2 contains a conserved putative CDK consensus site cluster.
(A). A Clustal Omega multiple sequence alignment of three putative CDK
phosphorylation sites, S525, S624, S726, in FANCD2 demonstrates strong
evolutionary conservation. (B) Region of the mouse Fancd2 crystal structure
represented as both surface and ribbons with S/P CDK consensus (teal) and the
monoubiquitination site (yellow) indicated, using the program Discovery Studio. (C)
FA-D2 cells stably expressing empty, FANCD2-WT, FANCD2-TA, and FANCD2TD were incubated in the absence (-) and presence (+) of 250 nM MMC for 18 h, and
whole-cell lysates were immunoblotted with antibodies to FANCD2, V5, FANCI and
α-tubulin.

The

FANCD2-V5

and

FANCI

L/S

ratios

are

the

ratios

of

monoubiquitinated to nonubiquitinated protein, and were calculated by measuring
protein band intensities using ImageJ image processing and analysis software
(http://rsb.info.nih.gov/ij/).
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putative CDK cluster, we generated two missense mutants in S525, S624, S726. These
sites were mutated into either phospho-dead triple alanine (TA) or phospho-mimetic
triple aspartic acid (TD) mutants. The FANCD2 cDNAs were cloned into the
pLenti6.2 lentiviral vector that contains a carboxy-terminal V5 tag. FA-D2 patientderived cells were used to stably express the empty vector, wild type FANCD2 and the
missense mutants. To determine the consequences of mutating the putative CDK site
cluster, the FA-D2 cell lines were then treated with and without MMC to determine
their monoubiquitination efficiency (Fig. 6C). Although these mutations did not
abrogate FANCD2 monoubiquitination, the TA mutant is constitutively activated and
the TD mutant is unable to elicit a monoubiquitination response with the addition of
damage. FANCI monoubiquitination is unaffected by the mutation of the FANCD2
phosphorylation sites. To further study the functional effect of mutating these
conserved phosphorylation residues, FA-D2 + empty, FANCD2-WT, TA, and TD
cells were incubated with and without either HU or aphidicolin (APH) (Fig. S5). As
we believe these residues are important in non-DNA damage inducible activation of
FANCD2, it is important to explore DNA replication inhibitors, as FANCD2 is active
during S phase of the cell cycle. HU transiently stalls replication by causing an
imbalance in the deoxyribonucleoside triphosphate pool and APH inhibits DNA
polymerase α [25,26]. Similar to the results obtained when treating with MMC, the TA
mutant appears to be constitutively monoubiquitinated, while the TD mutant fails to
become monoubiquitinated following exposure to the replicative inhibitors.
Interestingly, when looking at CHK1 pS345 and RPA pS3/4, both mutants have an
increase without the addition of treatment. These are markers for blocked DNA
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replication, suggesting that mutating these phosphorylation sites causes inefficient
DNA replication. Taken together, these results demonstrate the importance of these
sites in FANCD2 function and further analysis must be performed to determine their
mechanism of action and specific purpose in DNA replication.

Discussion
Although FANCD2 has been shown to function in unperturbed S phase of the cell
cycle, how this is regulated has not been studied [16]. In this study, with the use of
lambda phosphatase assays, we have revealed novel DNA damage-independent
phosphorylation of FANCD2. Several cell lines show FANCD2 having an increase in
electrophoretic mobility through an SDS Page gel with the addition of lambda
phosphatase, indicating the cleavage of phosphate groups from the protein during
incubation. This variance is not seen in FANCI, even after the addition of MMC.
Although we know FANCI is phosphorylated by ATM/ATR with the addition of
damage, this inability to visualize a molecular weight shift difference, due to
phosphate cleavage, could be explained by how extensive the phosphorylation is [15].
Currently, six S/TQ sites have been described to be phosphorylated by ATM/ATR
[14]. The limited number of residues phosphorylated could be the reason for no visible
shift difference seen in this assay. FANCD2 and FANCI are very large proteins, 1451
and 1328 amino acids, respectively [27]. In order to see this slight shift in protein
molecular weight, due to their size, the immunoblot must be extensively run and the
ability of FANCD2 phosphorylation to be visualized could mean it is extensively
phosphorylated. It is important to note that the shift is also seen with incubation with
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the second phosphatase, PP1. Interestingly, we have found that maximal FANCD2
phosphorylation, as seen through the lambda phosphatase assay, occurs at S phase.
This has been visualized by double thymidine block, as well as a nocodazole block.
This suggests that FANCD2s function in the cell cycle could be regulated through
phosphorylation.
DNA damage inducible FANCD2 phosphorylation has been widely studied, so
it is necessary to determine if the key regulatory proteins involved in this well-known
posttranslational modification are essential for the non-DNA damaging regulation of
FANCD2 [12,16,28]. With the use of patient fibroblast and lymphoblasts, we found
that the extensive phosphorylation of FANCD2, in S phase, is unaffected by the
absence of ATM, ATR, and FANCA. Due to FANCD2s monoubiquitination in S
phase and, now seen, phosphorylation, we next wanted to determine if these
posttranslational modifications were reliant on one another [16]. In using FA-D2
patient cells expressing FANCD2-K561R, the monoubiquitination deficient mutant,
this shift in FANCD2 in the presence of lambda phosphatase is still observed. This
would indicate that this phosphorylation event occurs upstream of monoubiquitination
or is monoubiquitination-independent. Importantly, with the addition of the
phosphatase throughout this study, monoubiquitinated FANCD2 is still present. This
suggests

that

this

monoubiquitinated

phosphorylation
FANCD2

and

does

not

affect

monoubiquitination

the
is

stabilization

not

essential

of
for

phosphorylation.
If FANCD2 is indeed phosphorylated during the cell cycle, the potential kinase
responsible is a CDK. As mentioned, several DNA repair proteins are phosphorylated
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by CDKs, so we decided to determine if FANCD2 was a substrate of CDK
phosphorylation [19,20]. In using two different cell systems and an antibody, that
specifically recognizes substrates of CDKs through its known consensus sequence; we
found that FANCD2 is potentially a substrate of CDK. To try to determine which
residues are phosphorylated and narrow down our sites of interest, we used the U2OS
3XFLAG FANCD2 immunoprecipitation to enrich for phospho peptides and analyze
by mass spectrometry. Several ATM/ATR sites were enriched, however, a putative
CDK consensus site that has not been studied due to its lack of sequence conservation
was also found, S592. We then optimized several CDK inhibitors to try to focus on a
specific

CDK

responsible.

Correlating

with

our

finding

that

FANCD2s

phosphorylation is maximal during S phase, the inhibitor Purvalanol A seemed to limit
FANCD2s molecular weight shift with the addition of lambda phosphatase. This
inhibitor is specific towards CDK2, with some inhibition of CDK1 [29]. We further
compared the CDK1 specific inhibitor, RO-3306, and Purvalanol A and found that
incubation with the CDK2 inhibitor for 4 and 8 h limited FANCD2s phosphorylation.
This suggests that FANCD2s phosphorylation during S phase is regulated by CDK2.
Through initial sequence and structural analysis, several important putative
CDK phosphorylation sites have been discovered. The CDK S/P residues S525, S624,
and S726 were highly conserved amongst various species and are situated proximal to
FANCD2s monoubiquitination site and form a cluster with the mass spectrometry
phospho peptide found, S592. This site, however, is located on a short uncrystallized
loop in FANCD2. Through site-directed mutagenesis, S525, S624, S726 were mutated
to alanines (TA), phospho-dead, or aspartic acid (TD), phospho-mimetic, residues.
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Originally, due to FANCD2s extensive phosphorylation occurring when it is
monoubiquitinated in S phase, we hypothesized that these sites may activate
FANCD2. Surprisingly, when FA-D2 patient cells expressing the phosphorylation
mutants were treated with MMC, the phospho-dead mutant is constitutively
monoubiquitinated and the phospho-mimetic

mutant

is

unable

to

induce

monoubiquitination after damage. This would indicate, not only the importance of
these residues in FANCD2s function, but also that phosphorylation at these sites may
inhibit FANCD2 monoubiquitination. Although maximal FANCD2 phosphorylation is
seen during S phase, these sites may not play a role in that function, but instead have a
novel regulatory effect on FANCD2 for its inactivation. As we are interested in DNA
damage-independent regulation of FANCD2 and we know it functions at stalled
replication forks in unperturbed S phase, the FA-D2 cells were treated with two DNA
replication inhibitors. With the addition of APH or HU, FANCD2-TA is constitutively
monoubiquitinated and FANCD2-TD is unable to show a response. Both mutations,
however, have an increase in CHK1 pS345 and RPA pS4/8, indicating replication is
blocked in both cases. Based on these findings, we predict that although these sites
may not be linked to FANCD2s cell cycle phosphorylation, they have an important
effect on FANCD2 function in response to DNA damaging and replicative stress
inducing agents. Further analysis on these mutants must be done in order to (A)
determine if CDK2 is the kinase responsible for this phosphorylation, (B) establish the
function of this posttranslational modification on the FA-BRCA pathway, and (C)
extensively characterize how mutation of these residues affect FANCD2 function.
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Materials and Methods
Cell culture
COS-7, HeLa, U2OS, U2OS 3X FLAG FANCD2, BJTERT, PEBS, YZ5, 6914, and
6914 + FANCA cells were grown in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 12% v/v FBS, L-glutamine and penicillin/streptomycin. 066 and
PD7L cells were grown in Roswell Park Memorial Institute medium (RPMI)
supplemented with 18% v/v FBS, L-glutamine and penicillin/streptomycin. 293FT
viral producer cells (Invitrogen) were cultured in DMEM containing 12% v/v FBS, 0.1
mM non-essential amino acids (NEAA), 1% v/v L-glutamine, 1 mM sodium pyruvate
and 1% v/v penicillin/streptomycin. PD20 FA-D2 (FANCD2hy/-) cells were purchased
from Coriell Cell Repositories (Catalog ID GM16633). These cells harbor a
maternally inherited A-G change at nucleotide 376 that leads to the production of a
severely truncated protein, and a paternally inherited missense hypomorphic (hy)
mutation leading to a R1236H change [30]. To generate stable lines expressing wild
type or mutant FANCD2, FA-D2 cells were infected with pLenti6.2-FANCD2
(Invitrogen) lentivirus, followed by selection in DMEM supplemented with 15% v/v
FBS, L-glutamine, penicillin/streptomycin and 2 μg/ml blasticidin. Cells were treated
with the CDK inhibitors Olomoucine (Acros), Olomoucine II (Santa Cruz), Purvalanol
A (Santa Cruz), RO-3306 (Santa Cruz), and Roscovitine (Acros) as indicated.

Antibodies and immunoblotting
For immunoblotting analysis, cell pellets were washed in PBS and lysed in 2% w/v
SDS, 50 mM Tris-HCl, 10 mM EDTA followed by sonication for 10 s at 10%
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amplitude using a Fisher Scientific Model 500 Ultrasonic Dismembrator. Proteins
were resolved on NuPage 3-8% w/v Tris-Acetate or 4-12% w/v Bis-Tris gels
(Invitrogen) and transferred to polyvinylidene difluoride (PVDF) membranes. The
following antibodies were used: rabbit polyclonal antisera against FANCD2 (NB100182; Novus Biologicals), FANCI (A301-254A, Bethyl), ATR (ab10312, Abcam),
ATM (C2C1, Genetech), CHK1 (2345, Cell Signaling), FANCA (ABP-6201,
Cascade), and pS CDK (9477, Cell Signaling), RPA (NA18, Calbiochem), FLAG
(F7425, Sigma),and mouse monoclonal sera against α-tubulin (MS-581-PO,
Neomarkers), cyclin A (SC751, Santa Cruz), CHK1 pS345 (2348, Cell Signaling),
RPA pS4/8 (A300-245A, Bethyl), and V5 (13202, Cell Signaling).

Immunoprecipitation
FA-D2 + LacZ, FA-D2 + FANCD2-V5, U2OS, and U2OS 3XFLAG FANCD2 cells
were lysed in Triton-X lysis buffer (50 mM Tris.HCl pH 7.5, 1% v/v Triton X-100,
200 mM NaCl, 5mM EDTA, 2mM Na3O4V, Protease inhibitors (Roche), and 0.153g
B-glycerophosphate) on ice for 15 min followed by sonication for 10 s at 10%
amplitude using a Fisher Scientific Model 500 Ultrasonic Dismembrator. V5 or
FLAG-agarose were washed and blocked with NETN100 (20 mM Tris-HCl pH 7.5,
0.1% NP-40, 100 mM NaCl, 1 mM EDTA, 1 mM Na3O4V, 1 mM NaF, protease
inhibitor (Roche)) + 1% BSA and the final wash and resuspension was done in TritonX lysis buffer. Lysate was then incubated with appropriate agarose at 4°C for 2 h,
nutating. Beads were then washed in Triton-X lysis buffer and boiled in 1× NuPAGE
buffer (Invitrogen) and analyzed for the presence of proteins by SDS-PAGE and
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immunoblotting or stained using Colloidal Blue Staining Kit (Invitrogen) for mass
spectrometry.

Plasmids, site-directed mutagenesis, and transient transfections
The full length FANCD2 cDNA sequences were TOPO cloned into the pENTR⁄DTOPO (Invitrogen) entry vector, and subsequently recombined into the pLenti6.2/V5DEST (Invitrogen) destination vector and used to generate lentivirus for the generation
of stable cell lines. The TA and TD cDNA were generated by site-directed mutagenesis
of the wild type FANCD2 cDNA using the Quikchange Site-directed Mutagenesis Kit
(Stratagene). The forward and reverse oligonucleotide sequences used are as follows:
TA:

S726A-FP

5‟-

AGGCCAAAAATTGGTGGCTCCGCTGTGCCTGGC-3‟,

S624A-FP 5‟- TCCTGCAGTGAGCAGGCTCCTCAGGCCTCTGCAC-3‟, S525AFP

5‟-

CTGGATAACATAGCCCCTCAGCAAATACGAAAACTCTTCTATGTTCTCAGC
AC-3‟; S726A-RP 5‟-

GCCAGGCACAGCGGAGCCACCAATTTTTGGCCT-3‟,

S624A-RP 5‟- GTGCAGAGGCCTGAGGAGCCTGCTCACTGCAGGA-3‟, S525ARP

5‟-

GTGCTGAGAACATAGAAGAGTTTTCGTATTTGCTGAGGGGCTATGTTATCC
AG -3‟. TD: S726D-FP 5‟-AGGCCAAAAATTGGTGGATCCGCTGTGCCTGGC3‟,

S624D-FP

5‟-

TCCTGCAGTGAGCAGGATCCTCAGGCCTCTGCAC-3‟,
5‟-

S525D-FP

CTGGATAACATAGACCCTCAGCAAATACGAAAACTCTTCTATGTTCTCAGC
AC-3‟;

S726D-RP

5‟-GCCAGGCACAGCGGATCCACCAATTTTTGGCCT-3‟,
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S624D-RP 5‟- GTGCAGAGGCCTGAGGATCCTGCTCACTGCAGGA-3‟, S525DRP

5‟-

GTGCTGAGAACATAGAAGAGTTTTCGTATTTGCTGAGGGTCTATGTTATCC
AG-3‟.

Lambda phosphatase assay
Cells were harvested and pellets were split into two, lysed in either lambda
phosphatase lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 mM EGTA, 1
mM dithiothreitol, 2 mM MnCl2, 0.01% Brij35, 0.5% NP-40, and protease inhibitor)
or lambda phosphatase buffer with the addition of phosphatase inhibitors, 2 mM
Na₃VO₄ and 5 mM NaF for 15 min at 4oC followed by sonication for 10 s at 10%
amplitude using a Fisher Scientific Model 500 Ultrasonic Dismembrator. Whole-cell
lysates were incubated with or without 30 U of lambda phosphatase pr 10 U of PP1for
2 h at 30°C, or for the times indicated. Proteins were resolved on NuPage 3-8% w/v
Tris-Acetate, 4-12% w/v Bis-Tris gels (Invitrogen), or 6% SuperSep Phos-tag (Wako
Pure Chemical Industries) and transferred to polyvinylidene difluoride (PVDF)
membranes. Larger proteins were resolved for 5 h on ice.

Cell-cycle synchronization
HeLa cells or the indicated fibroblast or lymphoblast lines were synchronized by
double thymidine block method. Cells were treated with 2.5 mM thymidine for 18
hours, thymidine-free media for 10 hours, and 2.5 mM thymidine for 18 hours to arrest
the cell cycle at G1/S. Cells were washed twice with phosphate-buffered saline (PBS)
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and released in DMEM + 12% FBS, L-glutamine, and penicillin/streptomycin and
analyzed at various time intervals by lambda phosphatase assay and immunoblotting,
or flow cytometry. For synchronization in M phase, a nocodazole block was used.
Cells were treated with 0.1 μg/mL nocodazole (Sigma) for 15 hours, and the
nonadherent cells were collected and washed with PBS, followed by resuspension in
DMEM without nocodazole and replated in DMEM 12% FBS, L-glutamine, and
penicillin/streptomycin.

Cell-cycle analysis
Cells collected from synchronization were resuspended in 0.1 mL PBS and fixed by
adding 1 mL ice-cold ethanol and stored at -20oC until analysis. Cells were then
washed in PBS and incubated in 0.3-0.5 mL RNase solution (1X RNase) for 10 min at
37oC, then stored on ice. Cells were then incubated on ice for 5-10 min in 50 μg/mL
propidium iodide (Sigma). DNA content was measured

by BD FACSVerse flow

cytometer system.

Acknowledgements
We thank members of the Howlett laboratory for critically reading this manuscript
and for helpful discussions. This work was supported by National Institutes of
Health/National Heart, Lung and Blood Institute grant R01HL101977 (NGH);
Department of Defense Bone Marrow Failure Research Program New Investigator
Award W81XWH-11-1-0318 (NGH); Rhode Island IDeA Network of Biomedical
Research Excellence (RI-INBRE) grant P20RR016457-09 from the National Center

138

for Research Resources (Zahir A. Shaikh, PI/NGH, faculty development); and
National Science Foundation EPSCoR grant #1004057.

139

References
1. FARF I (2003) Fanconi Anemia: Standards for Clinical Care; Joyce Owen PD,
Lynn Frohnmayer, M.S.W., and Mary Ellen Eiler, editor. Eugene, Oregon:
Fanconi Anemia Research Fund, Inc. 172 p.
2. Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, et al. (2013) Mutations in
ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia.
Am J Hum Genet 92: 800-806.
3. Kashiyama K, Nakazawa Y, Pilz DT, Guo C, Shimada M, et al. (2013) Malfunction
of Nuclease ERCC1-XPF Results in Diverse Clinical Manifestations and
Causes Cockayne Syndrome, Xeroderma Pigmentosum, and Fanconi Anemia.
Am J Hum Genet 92: 807-819.
4. Kim H, D'Andrea AD (2012) Regulation of DNA cross-link repair by the Fanconi
anemia/BRCA pathway. Genes Dev 26: 1393-1408.
5. Moldovan GL, D'Andrea AD (2009) How the fanconi anemia pathway guards the
genome. Annu Rev Genet 43: 223-249.
6. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, et al. (2001)
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.
Mol Cell 7: 249-262.
7. Nakanishi K, Taniguchi T, Ranganathan V, New HV, Moreau LA, et al. (2002)
Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell
Biol 4: 913-920.

140

8. Sims AE, Spiteri E, Sims RJ, 3rd, Arita AG, Lach FP, et al. (2007) FANCI is a
second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct
Mol Biol 14: 564-567.
9. Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER, 3rd, Hurov KE, et al.
(2007) Identification of the FANCI protein, a monoubiquitinated FANCD2
paralog required for DNA repair. Cell 129: 289-301.
10. MacKay C, Declais AC, Lundin C, Agostinho A, Deans AJ, et al. (2010)
Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA
damage by monoubiquitinated FANCD2. Cell 142: 65-76.
11. Yamamoto KN, Kobayashi S, Tsuda M, Kurumizaka H, Takata M, et al. (2011)
Involvement of SLX4 in interstrand cross-link repair is regulated by the
Fanconi anemia pathway. Proc Natl Acad Sci U S A 108: 6492-6496.
12. Taniguchi T, Garcia-Higuera I, Xu B, Andreassen PR, Gregory RC, et al. (2002)
Convergence of the fanconi anemia and ataxia telangiectasia signaling
pathways. Cell 109: 459-472.
13. Ho GP, Margossian S, Taniguchi T, D'Andrea AD (2006) Phosphorylation of
FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell
Biol 26: 7005-7015.
14. Ishiai M, Kitao H, Smogorzewska A, Tomida J, Kinomura A, et al. (2008) FANCI
phosphorylation functions as a molecular switch to turn on the Fanconi anemia
pathway. Nat Struct Mol Biol 15: 1138-1146.

141

15. Sareen A, Chaudhury I, Adams N, Sobeck A (2012) Fanconi anemia proteins
FANCD2 and FANCI exhibit different DNA damage responses during Sphase. Nucleic Acids Res.
16. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, et al.
(2002) S-phase-specific interaction of the Fanconi anemia protein, FANCD2,
with BRCA1 and RAD51. Blood 100: 2414-2420.
17. Schlacher K, Wu H, Jasin M (2012) A Distinct Replication Fork Protection
Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2.
Cancer Cell 22: 106-116.
18. Yeo JE, Lee EH, Hendrickson E, Sobeck A (2014) CtIP mediates replication fork
recovery in a FANCD2-regulated manner. Hum Mol Genet.
19. Ruffner H, Jiang W, Craig AG, Hunter T, Verma IM (1999) BRCA1 is
phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2
phosphorylation site. Mol Cell Biol 19: 4843-4854.
20. Falck J, Forment JV, Coates J, Mistrik M, Lukas J, et al. (2012) CDK targeting of
NBS1 promotes DNA-end resection, replication restart and homologous
recombination. EMBO Rep 13: 561-568.
21. Cohen PT, Cohen P (1989) Discovery of a protein phosphatase activity encoded in
the genome of bacteriophage lambda. Probable identity with open reading
frame 221. Biochem J 260: 931-934.
22. Kinoshita E, Kinoshita-Kikuta E, Ujihara H, Koike T (2009) Mobility shift
detection of phosphorylation on large proteins using a Phos-tag SDS-PAGE
gel strengthened with agarose. Proteomics 9: 4098-4101.

142

23. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G (1992) Cyclin A is
required at two points in the human cell cycle. EMBO J 11: 961-971.
24. Nigg EA (1995) Cyclin-dependent protein kinases: key regulators of the
eukaryotic cell cycle. Bioessays 17: 471-480.
25. Koc A, Wheeler LJ, Mathews CK, Merrill GF (2004) Hydroxyurea arrests DNA
replication by a mechanism that preserves basal dNTP pools. J Biol Chem 279:
223-230.
26. Krokan H, Wist E, Krokan RH (1981) Aphidicolin inhibits DNA synthesis by
DNA polymerase alpha and isolated nuclei by a similar mechanism. Nucleic
Acids Res 9: 4709-4719.
27. Boisvert RA, Howlett NG (2014) The Fanconi anemia ID2 complex: dueling saxes
at the crossroads. Cell Cycle 13: 2999-3015.
28. Andreassen PR, D'Andrea AD, Taniguchi T (2004) ATR couples FANCD2
monoubiquitination to the DNA-damage response. Genes Dev 18: 1958-1963.
29. Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, et al. (1998)
Exploiting chemical libraries, structure, and genomics in the search for kinase
inhibitors. Science 281: 533-538.
30. Timmers C, Taniguchi T, Hejna J, Reifsteck C, Lucas L, et al. (2001) Positional
cloning of a novel Fanconi Anemia gene, FANCD2. Molecular Cell 7: 241248.

143

APPENDIX I

Conclusion
Although FANCD2 is essential for proper function of the FA-BRCA pathway
and subsequent preservation of chromosome stability, there are many facets
concerning its regulation, function, and domain architecture that remain elusive to
date. Thus far, key FANCD2 functions include recruitment of the structure-specific
endonucleases,

SLX4

and

FAN1,

nucleosome

remodeling

and

assembly,

transcriptional activation of the tumor suppressor gene TAp63, replisome surveillance
of chromosomal fragile sites, as well as, resolution of stalled replication forks.
FANCD2 is an orphan protein, meaning there are no recognizable domains found in
the protein sequence. Several groups, our lab included, have focused on analyzing the
domain structure of FANCD2 and have discovered important domains in FANCD2.
An EDGE motif was found to be essential for ICL-sensitivity [1]. A PIP-motif was
discovered to be necessary for the interaction between FANCD2 and PCNA and is
required for efficient FANCD2 monoubiquitination and repair [2]. A CUE ubiquitin
binding domain in FANCD2 was needed for interaction with FANCI, as well as,
efficient ICL repair [3]. It was known that FANCD2 functions in the nucleus;
however, no experiments prior to my graduate research had examined how FANCD2
is transported for ICL repair.
One project that was comprehensively studied during my graduate research,
focused on the identification and characterization of a putative NLS in the amino
terminus of FANCD2 [4]. In this research, through initially fusing a predicted NLS
region to GFP, we discovered that the first 58 amino acids of FANCD2 are required to
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promote GFP nuclear localization. This region contained two bipartite NLSs, however,
both were found to be essential for localization. To determine if FANCD2 is
transported in an importin-α/β manner, treatment with a known inhibitor of this
pathway, ivermectin, caused GFP localization to be abolished even with the NLS
fused. In creating FANCD2 truncation mutants, localization and FANCD2 function
was abrogated without the FANCD2 NLS. FANCD2 was unable to form nuclear foci,
become monoubiquitinated, or bind to chromatin. Deletion of the NLS also had an
effect on FANCIs chromatin localization and monoubiquitination, albeit it was not
abolished, indicating that a subset of FANCI was transported to the nucleus via
FANCD2. Mutating three highly conserved, positively charged residues, in FANCD2
caused an intermediate phenotype, suggesting these sites are important for FANCD2s
localization. Together, these findings suggest that FANCD2 and a subset of FANCI
are transported to the nucleus through FANCD2s amino terminus NLS and its
subsequent interaction with importin-α/β. Once in the nucleus, FANCD2 and FANCI
bind

to

DNA

and

are

phosphorylated

by

ATM/ATR,

triggering

the

monoubiquitination of FANCD2 and FANCI by the core complex.
As mentioned, FANCD2 and FANCI are phosphorylated by ATM/ATR in
response to DNA damaging agents in order to facilitate the repair of DSBs [5-7].
However, it has been demonstrated that FANCD2 is monoubiquitinated during
unperturbed S phase of the cell cycle and functions to protect stalled replication forks
from MRE11 degradation [8,9]. FANCD2s DNA damage-independent regulation has
not been described. Through the utilization of lambda phosphatase assays in my most
recent project, I found that FANCD2 is extensively phosphorylated, specifically in S
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phase of the cell cycle. This led us to hypothesize that this is how FANCD2 is being
regulated in the absence of damage. In synchronizing various cell lines, we found that
this phosphorylation pattern is independent of the major DNA damage kinases, ATM
and ATR, as well as the core complex member FANCA. Interestingly, we also showed
that the ability of FANCD2 to become monoubiquitinated did not alter FANCD2s
phosphorylation and the monoubiquitinated form of FANCD2 persists even with the
addition of the phosphatase enzyme. This demonstrates that the DNA damage
independent

phosphorylation

of

FANCD2

is

also

independent

of

its

monoubiquitination. As this phosphorylation is maximal at S phase, we found that
FANCD2 is indeed a substrate of CDK phosphorylation. To narrow down which
residues in FANCD2 could be phosphorylated by CDK, we found several conserved
SP sites that were surprisingly clustered around FANCD2s site of monoubiquitination.
These sites were then mutated to phospho-dead alanine (TA) residues or phosphomimetic asparagine (TD) residues. Currently, we have found that these sites do alter
FANCD2s ability to become monoubiquitinated with the addition of MMC or DNA
replication inhibitors. The TA mutant is constitutively monoubiquitinated and the TD
mutant does not elicit a response. These preliminary findings suggest that these sites
are phosphorylated in order to inhibit FANCD2s monoubiquitination. These FANCD2
mutants need to be further studied to determine the function of FANCD2
monoubiquitination inhibition. Ultimately, due to the importance of FANCD2 in
aspects of DNA repair and DNA replication, this protein should be further
characterized to potentially discover significant therapeutic implications for FA that
allow for tailored prophylactic and chemotherapeutic measures to be adopted.
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APPENDIX II

Supplemental information for manuscript II: “Coordinate Nuclear Targeting of the
FANCD2 and FANCI Proteins via a FANCD2 Nuclear Localization Signal”

Supplemental materials and methods
Generation of FANCD2-GFP fusion vectors
To fuse amino acids 1-27 of FANCD2 to the amino terminus of GFP to generate
D2-1-27-GFP, we PCR amplified the coding sequence of amino acids 1-27 using the
following forward and reverse primers: FP, 5‟-AAAGAGCTCCACCATGGTTTCC3‟; RP, 5‟-TATCTGCAGTGGTTGCTTCCTGGT-3‟. Similarly, D2-24-58-GFP was
generated by PCR amplifying amino acids 24-55 of FANCD2 using the following
primers:

FP,

5‟-ATAGAGCTCCACCATGAGGAAGCAACCACT-3‟;

GGCGCTGCAGAATAATTCCTGATATCTTAAGA-3‟.

RP,

D2-1-58-GFP

5‟was

generated by PCR amplifying amino acids 1-58 of FANCD2 using the following
primers:

FP,

5‟-AAAGAGCTCCACCATGGTTTCC-3‟;

CCCCTGCAGAATAATTCCTGATATC-3‟.

All

amplified

RP
fragments

5‟were

directionally cloned into the SacI-PstI site of pGFP-N1 (Clontech). DNA fragments
were amplified using an Eppendorf Mastercycler ep thermal cycler using the following
conditions: Thirty cycles of denaturation at 95°C for 30 sec, annealing at 59-65°C for
1 min, and extension at 68°C for 1 min, followed by cooling to 4°C.
Supplemental Figures
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Figure S1. FANCD2 contains a highly conserved amino-terminal nuclear
localization signal, which facilitates nuclear expression of GFP. (A) cNLS mapper
(http://nls-mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi) was used to analyze
the FANCD2 amino acid sequence for importin /-dependent nuclear localization
signals (NLSs), and identified amino acids 2-58 as harboring several putative high
scoring bipartite NLSs (B). (C) D2-1-58-GFP localizes primarily to the nucleus.
IMR90 cells were transiently transfected with the indicated GFP constructs and
analyzed by inverted fluorescence microscopy. (D) HeLa cells were transiently
transfected with wild type GFP (GFP-WT) or GFP fused to amino acids 1-58 of
FANCD2 (D2-NLS-GFP), incubated in the absence or presence of 25 M ivermectin
for 20 h, followed by analysis by inverted fluorescence microscopy. (E) The % of
cells exhibiting both cytoplasmic and nuclear (Cyto. + Nucl.) and exclusive nuclear
(Nuclear) staining were scored and plotted. Error bars represent the standard errors of
the means from two independent experiments. ***, p < 0.001. (F) HeLa cells were
transiently transfected with the indicated GFP constructs and 24 h later cell pellets
were fractionated into soluble (S) and chromatin (C) fractions. Fractions were resolved
by SDS-PAGE and immunoblotted with antibodies to GFP, α-tubulin, and H2A. W,
unfractionated whole-cell extract. (G) The integrated densities of the protein bands
from Fig. S1F were quantified using ImageJ image processing and analysis software,
and plotted. While the integrated band densities for a single experiment are shown,
these experiments were repeated several times with very similar findings. WCE,
whole-cell

extract.
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Figure S2. The FANCD2 NLS is required for the nuclear localization of a subset
of FANCI. (A) KEAE FA-D2 hTERT cells or KEAE FA-D2 hTERT cells stably
expressing FANCD2-WT were incubated in the absence (NT) or presence of MMC
for 24 h, fixed, stained with rabbit polyclonal anti-FANCD2 or anti-FANCI antibody
and counterstained with phalloidin and DAPI. AF-488, Alexa Fluor 488. (B) FA-D2
cells stably expressing FANCD2-WT, FANCD2-∆N57, or FANCD2-∆N100 were
incubated in the absence (NT) or presence of MMC for 24 h, fixed, stained with
mouse monoclonal anti-V5 (red) to detect V5-tagged FANCD2 and rabbit polyclonal
anti-FANCI (green) and counterstained with DAPI (blue). IF microscopy was
performed with (+ Pre-Perm) and without (No Pre-Perm) a pre-permeabilization step
(see Materials and Methods). The pre-permeabilization step leads to complete loss of
fluorescent signal for FANCD2-N57 and FANCD2-N100 because of the high
solubility of these proteins (see Fig. 2B), while this step is necessary for the resolution
of

FANCI

fluorescence
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signal.
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Figure S3. The FANCD2 NLS is required for efficient FANCI chromatin
association. FA-D2 cells stably expressing FANCD2-WT (WT), FANCD2-∆N57
(∆N57), FANCD2-∆N100 (∆N100) or FANCD2-3N (3N) were incubated in the
absence or presence of MMC for 18 h and cell pellets were fractionated into soluble
and chromatin-associated fractions (see Figs. 4B and C). The total integrated densities
of the chromatin-associated (C) nonubiquitinated and monoubiquitinated FANCI
protein bands were quantified using ImageJ image processing and analysis software,
and plotted. While the integrated band densities for a single experiment are shown,
these experiments were repeated several times with similar findings. NT, not treated;
MMC,

MMC-treated.
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Figure S4. The FANCD2 NLS deletion mutants fail to rescue the MMC
sensitivity of FA-D2 cells. FA-D2 cells stably expressing FANCD2-WT, FANCD2K561R, FANCD2-∆N57, FANCD2-∆N100, or FANCD2-3N were treated with the
indicated concentrations of MMC for 7-10 days. Cells were fixed and stained with
crystal violet and percent survival calculated and plotted. Each measurement was
performed in triplicate and experiments were performed multiple times with similar
results. The 20% trimmed means ( X 20%) for all recorded measurements were
calculated and plotted. Error bars represent the standard errors of the means.
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APPENDIX III
Supplemental information for manuscript III: “Characterization of a Putative CDK
Phosphorylation Site Cluster in the FANCD2 Protein”

Supplemental Figures
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Figure S1. FANCD2 phosphorylation is maximal in S phase. U2OS cells were
synchronized double thymidine block and the cell cycle phase was determined by flow
cytometric analysis of DNA content. Whole-cell lysates were incubated in the absence
(-) and presence (+) of lambda phosphatase for 2 h at 30°C and immunoblotted with
antibodies against FANCD2, FANCI, and Cyclin A. AS, asynchronous whole-cell
lysate.
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Figure S2. Non-DNA damage inducible phosphorylation of FANCD2 is
independent of FANCD2 monoubiquitination. HeLa, FA-D2 cells with empty
plasmid or stably expressing FANCD2-WT, and FANCD2-K561R were incubated
with lambda phosphatase for 2, 4, 16 h at 30°C and immunoblotted against FANCD2.
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Figure S3. FANCD2 is a potential substrate of CDK phosphorylation. U2OS and
U2OS cells stably expressing 3X FLAG FANCD2-WT were immunoprecipitated with
anti-FLAG agarose and immune complexes were run on a coomassie gel. 3X FLAGFANCD2 bands were then cut out and sent for phospho enrichment and mass
spectrometry

analysis.
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Figure S4. FANCD2 contains a conserved putative CDK consensus site cluster.
FA-D2 cells stably expressing empty, FANCD2-WT, FANCD2-TA, and FANCD2TD were incubated in the absence (-) and presence (+) of 1 μM APH and 1 mM HU
for 24 h, and whole-cell lysates were immunoblotted with antibodies to FANCD2, V5,
FANCI, CHK1, CHK1 pS345, RPA, and RPA pS4/8. FANCD2-V5 and FANCI L/S
ratios

were

then

determined

169

as

described.
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